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A STUDY OF SERUM FETUIN-A LEVEL IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE 
ABSTRACT 
BACKGROUND AND OBJECTIVES: 
                     Chronic Kidney Disease (CKD) is characterized by excessive 
vascular calcification which in turn is associated with cardiovascular 
dysfunction. Inflammation and derangements in calcium-phosphorus 
metabolism seem to play an important role in the accelerated calcifying 
atherosclerosis seen in CKD. Fetuin-A is the prototype of a systemically acting 
inhibitor of extraskeletal calcification and is downregulated following 
inflammation. In the present study, serum Fetuin-A level was estimated in 
patients with CKD and its relationship with inflammation and alteration in 
calcium-phosphorus levels were analyzed. 
MATERIALS AND METHODS: 
  80 patients with CKD and 80 healthy controls were enrolled in 
the study. Serum levels of Fetuin-A, hsCRP, calcium, phosphorus, albumin and 
lipid profile were measured. Serum Fetuin-A was estimated by Enzyme Linked 
Immunosorbent Assay (ELISA). 
RESULTS: 
  Compared to controls, a significant reduction of serum Fetuin-A 
level was observed in patients with CKD and this reduction was gradual, 
beginning from the early stages of CKD. Serum Fetuin-A levels also showed a 
significant negative correlation with hsCRP and calcium-phosphorus levels and 
a significant positive correlation with albumin levels. 
CONCLUSION: 
                    The results of the present study indicate that in CKD, there is a 
progressive reduction in serum Fetuin-A levels along with the gradual decline 
in renal function. The chronic inflammatory state and the altered mineral 
metabolism prevailing in CKD could be responsible for the lowered levels of 
serum Fetuin-A. 
KEY WORDS: 
Chronic Kidney Disease, Fetuin-A, hsCRP, Inflammation  
   
INTRODUCTION 
                          Chronic kidney disease (CKD) refers to an irreversible 
progressive deterioration in renal function
1
. CKD is defined as either kidney 
damage or GFR < 60 ml/min/1.73 m
2
 for 3 months or more, irrespective of the 
cause. In CKD, there is a progressive and unrelenting loss of renal function 
which ultimately leads on to end stage renal disease
2
. 
                          CKD is a worldwide, chronic, non-communicable disease 
epidemic with adverse outcomes of renal failure, cardiovascular disease and 
premature death. In developed countries, it affects 10-15% of adult general 
population. Prevalence of CKD in India is 0.79%
21
. Diabetes mellitus and 
hypertension are responsible for 40-50% of all cases of CKD. 
                          Accelerated cardiovascular disease is a frequent complication 
of CKD. Over 80-90% of patients with CKD die primarily of cardiovascular 
disease, before reaching the need for dialysis
3
. This emphasizes the importance 
of early detection of cardiovascular disease, before the patients reach advanced 
stages of CKD. 
                        Alteration of mineral metabolism that occurs in CKD promotes 
vascular calcification. In addition, vascular calcification also involves the 
imbalance of equilibrium between calcification promoters and inhibitors. The 
presence of vascular calcification poses an increased risk of cardiovascular and 
all-cause mortality in patients with CKD
4
. 
                      CKD is also associated with chronic inflammation, which 
promotes endothelial dysfunction, vascular remodelling and progression of 
atherosclerosis. In CKD, progressive deterioration of renal function may also 
lead on to accumulation of uremic toxins and dyslipidemia, which in turn 
stimulate inflammation and result in atherosclerosis
5
.  
                      Hence in CKD, there exists an active interplay between 
atherosclerosis and vascular calcification through inflammation, against a 
background of severe calcium-phosphorus disturbances. This in turn 
contributes to the development of cardiovascular disease in patients with CKD. 
                     Serum Fetuin-A, an α2-glycoprotein is regarded as a negative 
acute phase reactant, that is down regulated following inflammation
6
. Further, 
Fetuin-A has also been identified as a potent circulating inhibitor of systemic 
calcification by inhibition of calcium-phosphate precipitation
7
. Measurement of 
serum Fetuin-A levels could therefore have a potential value to predict vascular 
calcification and hence the cardiovascular risk in CKD. 
                            Hence in the present study, the serum level of Fetuin-A was 
estimated in patients with CKD and the relationship between serum Fetuin-A, 
inflammation, abnormalities in calcium-phosphorus levels and dyslipidemia 
were analyzed.  
 
 
REVIEW OF LITERATURE 
                         The kidneys excrete metabolic waste products and have an 
essential homeostatic function by controlling the body solute and water status 
and the acid-base balance. In addition, the kidneys have important endocrine 
functions including production of calcitriol, erythropoietin and renin
8
. 
RENAL EXCRETORY MECHANISMS – AN OVERVIEW: 
RENAL GLOMERULAR FUNCTION: 
                      About 200L of plasma ultra filtrate enter the renal tubular lamina 
daily by glomerular filtration
9
. Glomerular filtration rate depends on the 
following factors: 
(i) Balance of pressures across the filtration barrier in the glomerulus 
(difference between the hydrostatic pressure in the glomerular 
capillaries which promote filtration, and the plasma oncotic pressure 
and hydrostatic pressure in Bowman’s space which oppose filtration) 
(ii) Rate of renal blood flow 
(iii) Total surface area of the glomerular capillaries 
GLOMERULAR FILTRATION BARRIER: 
                    An ultra filtrate of plasma passes from glomerular capillary blood 
into the space of Bowman’s capsule, through the glomerular filtration 
barrier
10,11
.  
 
The glomerular filtration barrier is made up of 3 layers: 
1. Capillary endothelium 
2. Basement membrane 
3. Podocytes 
Glomerular endothelial cells and podocytes have glycocalyx, a negatively 
charged surface coat. The glomerular basement membrane also contains 
negatively charged heparan sulphate, sialic acid and sialoproteins. These 
negative charges impede the passage of negatively charged molecules through 
the glomerular filtration barrier by electrostatic repulsion. 
RENAL TUBULAR FUNCTION:
8,12,13
 
                           When the plasma filtered into Bowman’s space enters the 
proximal tubule, the process of reabsorption takes place. From the 200L of 
plasma filtered daily, only about 2L of urine are formed. Almost all the 
reusable nutrients and the bulk of electrolytes are reclaimed from the proximal 
tubules, with fine homeostatic adjustments taking place more distally.  
                            The tubular cells do not actively deal with waste products like 
urea and creatinine to any significant degree. Most filtered urea is passed in 
urine, but some amount of it diffuses back passively from the collecting ducts 
with water; by contrast, some amount of creatinine is secreted into the tubular 
lumen. 
                         The tubular cells use adenosine tri-phosphate dependent active 
transport, sometimes selectively, against physicochemical gradients. Transport 
of charged ions tends to produce an electrochemical gradient that inhibits 
further transport. This is minimized by 2 processes: 
(i) ISOSMOTIC TRANSPORT: 
                        This occurs mainly in the proximal convulted tubules 
and reclaims the bulk of filtered essential constituents. Active 
transport of one ion leads to the passive movement of another ion of 
the opposite charge in the same direction along the electrochemical 
gradient. For example, isosmotic reabsorption of Na
+
 depends on the 
availability of negatively charged ions like Cl
-
. The process is 
“isosmotic” because the active transport of solute causes movement 
of equivalent amount of water in the same direction. Isosmotic 
transport also occurs to a lesser extent in the distal parts of the 
nephron. 
(i) ION EXCHANGE: 
                      This occurs mainly in the more distal parts of the 
nephrons and is important for fine adjustment after bulk reabsorption 
has taken place. Ions of the same charge, usually cations are 
exchanged and neither electrochemical nor osmotic gradients are 
created. For example, Na
+
 may be reabsorbed in exchange for K
+ 
and 
H
+ 
ions.
     
 
 
REQUIREMENTS FOR NORMAL RENAL FUNCTION:
 
                          The function of the two kidneys reflects the sum of the 
functions of their individual nephrons. For a nephron to function normally, the 
following conditions must be satisfied:
14
 
1. There must be free flow of blood through the glomerular capillaries. 
2. The glomerular filter must function normally. An adequate volume of 
filtrate must be produced, but the filter must restrict the passage of blood 
cells and proteins. 
3. The tubules must be able to selectively reabsorb important substances 
from the filtrate and to excrete other constituents into the filtrate. 
4. The urine formed by the nephron must be able to flow freely from the 
kidney into the bladder and out of the urethra. 
Derangement of any of these functions results in kidney disease.                  
 
                                 
 
 
 
 
 
                                  CHRONIC KIDNEY DISEASE  
                          Chronic kidney disease is a syndrome of persistent renal 
impairment involving the loss of both glomerular and tubular functions, such 
that the homeostatic functions of kidneys are compromised. 
                         In 2002, the United States National Kidney Foundation 
published the Kidney Disease Outcomes Quality Initiative (K/DOQI) 
guidelines, which provided a framework for the evaluation of CKD. 
DEFINITION OF CKD:
15 
                         CKD is defined as “either kidney damage for ≥ 3 months or a 
glomerular filtration rate < 60 ml/min/1.73 m
2
 for ≥ 3 months irrespective of 
the cause”. Kidney damage is defined by structural or functional abnormalities 
of the kidney with or without decreased glomerular filtration rate, manifesting 
by either, 
 Pathological abnormalities, (or) 
 Markers of kidney damage, including abnormalities in the composition 
of blood or urine, (or)  
 Abnormalities in imaging tests. 
STAGES OF CKD:
16 
                         The National Kidney Foundation-K/DOQI classification system 
for stages of CKD is based on the severity of the disease as indicated by the 
level of glomerular filtration rate. The higher stages represent lower GFR 
levels, regardless of the rate of progression or the specific cause. 
 
CKD 
STAGE 
                 DESCRIPTION GFR 
(ml/min/1.73m
2
) 
0 Individuals at increased risk ≥ 90 
1 Kidney damage with normal or increased 
GFR 
≥ 90 
2 Kidney damage with mild decrease in 
GFR 
60-89 
3 Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney failure   < 15 
 
GFR can be assessed by either 24 hours urinary creatinine clearance or from 
serum creatinine by using one of the following formulas:
17,18 
 Cock-Croft Gault formula 
 Modification of Diet in Renal Disease (MDRD) formula 
 CKD-Epidemiology Collaboration (CKD-EPI) equation 
 
 
EPIDEMIOLOGY: 
                               CKD is a worldwide threat to public health, but the true 
incidence and prevalence of CKD within a community are difficult to ascertain 
because, early to moderate CKD is usually asymptomatic
19
. CKD has remained 
largely as a ‘silent’ epidemic. 
                               According to World Health Organisation Global Burden of 
Disease Project, kidney and urinary tract diseases contribute to the global 
burden with approximately 8,50,000 deaths every year. Globally, CKD has 
been found to be the 17
th
 cause of disability and 12
th
 leading cause of death
20
. 
                               In India, the prevalence of CKD is 0.79% and 10% of 
patients with CKD are in the end stage renal disease
21,22
. 
NATURAL HISTORY OF CKD: 
                               It has been predicted that about two-thirds of normal adults, 
above the age of 40 years will experience a decrease in GFR, even though they 
might not have had any obvious kidney disease in the past, whereas in the 
remaining one-third of adults, GFR has been shown to remain stable. However, 
this decrease of GFR with age differs from the progressive deterioration of 
renal function that follows kidney damage and rarely requires therapy
23
. 
                               Most patients with CKD stages 3-5, progress relentlessly to 
end stage renal disease. The rate of progression of CKD depends on the 
following factors:
24 
 varies according to the underlying nephropathy 
 varies between individual patients 
 quality of control of glycemia and systemic hypertension 
 secondary to infections, dehydration or exposure to nephrotoxins like 
non-steroidal anti-inflammatory drugs or radiocontrast agents 
                       The rate of decline of GFR is fastest in patients with diabetic 
nephropathy, averaging ~ 10 ml/min/year. Rate of decline is also faster in 
polycystic kidney disease and chronic glomerulonephritis. 
RISK FACTORS OF CKD:
25,26 
                      There are various factors which affect initiation and 
progression of CKD. 
(i) Susceptibility factors 
- Increase the susceptibility to kidney damage  
(ii) Initiation factors 
- Directly initiate the kidney damage 
(iii) Progression factors 
- Cause worsening of kidney damage and faster decline in kidney 
function 
(iv) End stage factors 
- Increase the morbidity and mortality in kidney failure 
 
TYPES OF RISK FACTORS FOR CKD: 
RISK FACTORS EXAMPLES 
Susceptibility factors Older age, family history, racial or ethnic minority status, 
low birth weight, low income 
Initiation factors Diabetes, hypertension, urinary tract infection, lower 
urinary tract obstruction, drug toxicity like non-steroidal 
anti-inflammmatory drugs, autoimmune diseases, 
systemic infections 
Progression factors Poor glycemic control in diabetes, uncontrolled hyper 
tension, smoking, higher levels of proteinuria 
End stage factors Low serum albumin, anaemia, temporary vascular 
access, lower dialysis dose (Kt/V) 
 
AETIOLOGY OF CHRONIC KIDNEY DISEASE:
27,28 
(i) Congenital and inherited diseases: 
- Polycystic kidney disease 
- Medullary cystic disease 
- Alport’s syndrome 
- Tuberous sclerosis 
- Oxalosis 
- Congenital obstructive uropathy 
- Cystinosis 
(ii) Glomerular diseases: 
- Primary glomerulonephritis including focal glomerulosclerosis 
(iii) Secondary glomerular disease (Systemic Lupus Erythematosus, 
Polyangiitis, Wegener’s Granulomatosis, Haemolytic Uremic 
Syndrome, Thrombotic Thrombocytopenic Purpura, Amyloidosis, 
Diabetic Glomerulosclerosis, accelerated Hypertension, Systemic 
Sclerosis, Henosch-Schonlein Purpura, Sickle Cell Disease)  
(iv) Vascular diseases: 
- Hypertensive nephrosclerosis 
- Small and medium-sized vessel vasculitis 
- Renovascular disease 
(v) Tubulointerstitial diseases: 
- Tubulointerstitial nephritis - idiopathic, due to drugs (especially 
nephrotoxic analgesics), immunologically mediated 
- Schistosomiasis 
- Nephrocalcinosis 
- Reflux nephropathy 
- Balkan nephropathy 
- Tuberculosis 
- Myeloma kidney 
- Renal papillary necrosis (Diabetes, Sickle Cell Disease and Trait, 
Analgesic nephropathy) 
 
(vi) Urinary tract obstruction: 
- Calculus disease 
- Pelvic tumors 
- Retroperitoneal fibrosis 
- Prostatic disease 
- Schistosomiasis 
PATHOPHYSIOLOGY OF CKD: 
                    2 broad sets of mechanisms of damage are involved in the 
pathophysiology of CKD:
29 
(i) Initiating mechanisms that are specific to the underlying etiology like 
genetically determined abnormalities in kidney development or toxin exposure 
or immune complex deposition and inflammation.  
(ii) Progressive mechanisms that involve hyperfiltration and hypertrophy of the 
remaining viable nephrons. 
             The pathophysiologic progression of CKD is characterized by, 
                                • Glomerulosclerosis and 
                                • Tubulointerstitial inflammation and fibrosis 
GLOMERULOSCLEROSIS:
30 
                  This is characterized by 3 stages. Figure 1 shows the stages of 
glomerulosclerosis. 
Figure 1: STAGES OF GLOMERULOSCLEROSIS 
 
 
    
 
 
 
● Stage of inflammation: 
- Within the glomerular capillaries, endothelial cells are the first to be 
exposed to damage induced by hemodynamic, immunologic or 
metabolic insults. 
-  The glomerular endothelial injury is associated with reduction or loss of 
their physiologic anticoagulant and anti-inflammatory properties and 
acquisition of pro-coagulant and inflammatory characteristics. 
- This leads to attraction and activation of platelets and micro thrombus 
formation in glomerular capillaries. 
- These changes lead to the initiation of glomerular micro inflammation, 
with the attraction, adhesion and infiltration of glomerular tufts by 
inflammatory cells. 
● Stage of proliferation: 
            After endothelial injury and the ensuing micro inflammatory response, 
infiltrating monocytes interact with mesangial cells and stimulate their 
proliferation either through cell-cell interactions or through the release of 
mitogens. 
● Stage of fibrosis: 
- Under the control of fibrogenic growth factors like TGF-β1, 
proliferating and activated mesangial cells have the capacity to revert to 
a mesenchymal phenotype (myofibroblasts) which synthesize a range of 
extracellular matrix components. 
- The relative inability of the podocytes to replicate in response to injury 
may lead to their stretching along the glomerular basement membrane, 
thereby exposing its denuded areas, which in turn interact with parietal 
epithelial cells and form capsular adhesions. 
- The subsequent disruption of glomerular-tubular junction, result in 
atubular glomeruli. This may lead to misdirected filtration and 
accumulation of amorphous material in the paraglomerular space. 
TUBULOINTERSTITIAL INFLAMMATION AND FIBROSIS:
31 
                Like glomerulosclerosis, tubulointerstitial fibrosis also evolves in 
stages including inflammation, proliferation of interstitial fibroblasts, 
epithelial-mesenchymal transition and excessive deposition of interstitial extra 
cellular matrix (Figure 2). 
 
Figure 2: TUBULOINTERSTITIAL FIBROSIS 
                               
MECHANISMS: 
 Loss of renal mass leads to hyperfiltration of remaining nephrons which 
produces hypertension locally in the capillary tufts. This results in 
leakage of proteins into the tubular fluid. 
 Injury to the glomerulus also results in addition of activated mediators to 
the proteinuric filtrate. 
 As albumin is abundant in the filtrate, it binds to the activated mediators. 
These small albumin-bound molecules initiate the tubular inflammation. 
 These complex mixtures of proteinuric cytokines bathe the tubular 
epithelia which produce increased amounts of chemokines, fibroblast 
growth factor-2, TGF-β and platelet derived growth factor. 
 Proteinuric infiltrate also causes direct tubulo-interstitial injury by 
producing accumulation of proteins in the interstitial space and thereby 
activating the mediators that promote inflammation and fibrosis. 
 AngiotensinII which promotes glomerular hyperfiltration and 
hypertension also contributes to proteinuria. It may also increase the 
activity of growth factors and inflammatory cells that mediate 
tubulointerstitial fibrosis and scarring. 
 Also glomerular injury may reduce the peritubular perfusion and initiate 
local ischemia and hypoxia causing tubular atrophy and interstitial 
fibrosis. 
 
COMPLICATIONS OF CKD:
32 
                         As the renal function declines progressively, the kidney loses 
its regulatory capacity which results in various complications: 
(i) Fluid and electrolyte disturbances: 
                     Increased or reduced blood volume, low or high sodium 
levels, hyperkalemia, hyperphosphatemia, hypocalcemia, metabolic 
acidosis. 
(ii) Neurological abnormalities: 
                    Headache, irritability and sleep disorders, seizures, 
peripheral neuropathy, muscle twitchings, cramps, coma. 
(iii) Cardiovascular system: 
                   Hypertension, heart failure, cardiomyopathy, pericarditis 
(iv) Gastrointestinal tract: 
                    Nausea, vomiting, anorexia, gastrointestinal bleeding, 
gastritis, uremic fetor 
(v) Haematological abnormalities: 
                   Anaemia, bleeding, coagulation defect, infections 
(vi) Skin: 
                 Pruritus, pallor, hyperpigmentation, ecchymoses, uremic frost 
(vii) Metabolic and endocrinal abnormalities: 
            Glucose intolerance, secondary hyperparathyroidism, goitre, 
amenorrhoea, renal osteodystrophy 
COMPLICATIONS IN VARIOUS STAGES OF CKD: 
STAGES 1 & 2: 
 Patient is asymptomatic. 
 Blood urea nitrogen and serum creatinine are normal or near normal. 
 Acid-base, fluid and electrolyte balances are maintained through an 
adaptive increase of function in the remaining nephrons. 
STAGE 3: 
 Serum creatinine and blood urea nitrogen are elevated. 
 Serum levels of erythropoietin, calcitriol and paratharmone are usually 
abnormal. 
 Patients present with anaemia, hypertension, fluid retention and 
dyslipidemia. 
STAGE 4: 
 This stage is characterized by severe impairment of GFR involving a 
further loss of kidney function. 
 Along with features of stage 3, patients present with 
malnutrition,acidosis, hyperphosphatemia, hypocalcemia, hyperkalemia, 
amenorrhoea and  infertility. 
 
 
STAGE 5: 
This stage is defined by a GFR < 15 ml/min/1.73 m
2
 and is characterized by 
worsening of all the aforementioned findings along with bleeding diathesis, 
uremic encephalopathy, pericarditis and symptoms like fatigue, dysgeusia, 
anorexia, nausea and pruritus.  
CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: 
                        Cardiovascular disease is the most frequent cause of death 
among people with CKD. The overall mortality rate from cardiovascular 
disease in CKD patients has been found to be about 30 times greater than that 
of general population
33. CKD is therefore considered as a “cardiovascular risk 
equivalent”. 
                        In patients with CKD, cardiovascular disease is characterized by 
left ventricular hypertrophy, which results largely due to expansion of 
extracellular volume, anaemia and hypertension. Left ventricular remodelling 
and fibrosis may accompany left ventricular hypertrophy which ultimately 
results in several complications
34
. Figure 3 shows the mechanisms involved in 
the development of cardiovascular disease in CKD. 
                         Cardiovascular complications associated with CKD include 
myocardial infarction, angina pectoris, arrhythmias, cardiac failure, peripheral 
vascular disease, stroke and sudden death. The risk increases from early stages 
to advanced CKD for each of these conditions. 
 Fig.3: CARDIOVASCULAR DISEASE IN PATIENTS 
WITH CKD 
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CARDIOVASCULAR RISK FACTORS IN CKD:
35,36 
TRADITIONAL RISK FACTORS: 
- Age, Gender, Diabetes, Insulin Resistance, Hypertension, Smoking 
NON-TRADITIONAL/NOVEL RISK FACTORS: 
- Inflammation 
- Oxidative stress 
- Endothelial dysfunction 
- Anaemia 
- Hyperphosphatemia 
- Secondary hyperparathyroidism 
- Vascular calcification 
- Advanced Glycation End Products 
- Hyperhomocysteinemia 
DYSLIPIDEMIA IN CKD:
37,38
  
                              Progressive deterioration of renal function results in altered 
composition of blood lipids which in turn predisposes to the development of 
vascular disease. Renal dyslipidemia is characterized by the following features: 
 Hepatic apo-AI synthesis is decreased and lecithin cholesterol acyl 
transferase activity is reduced. This leads to decreased HDL-C levels. 
 Increased synthesis of apo-CIII, a competitive inhibitor of lipoprotein 
lipase, leads to elevated levels of VLDL-C and chylomicrons, which 
results in hypertriglyceridemia. Further, uremic toxins and secondary 
hyperparathyroidism reduces the levels of lipoprotein lipase which 
results in impaired catabolism of triglyceride rich lipoproteins. Insulin 
resistance associated with CKD also increases the VLDL-C levels. 
 Total and LDL-cholesterol levels are usually normal, but may be low in 
patients with concomitant inflammation and malnutrition. There is 
characteristic accumulation of small dense atherogenic LDL-C. 
 As GFR declines, the levels of high molecular weight isoforms of 
lipoprotein(a) increase, which is associated with increased cardio 
vascular risk. 
 The changes in lipoprotein composition and structure in CKD stimulate 
and amplify the already existing inflammatory mechanisms, which in 
turn results in endothelial dysfunction and atherosclerotic 
progression
39,40
.  
INFLAMMATION IN CKD:
41,42,43 
                              Most CKD patients are in a state of chronic inflammation. 
Various factors may be associated with a sustained inflammatory response in 
CKD which include, 
 Genetic background 
 Persistence of inflammatory conditions 
- Exogenous (Foreign, example: bacteria, viruses etc…) 
- Endogenous (Reactive oxygen species, glycated and oxidized adducts,    
  renin-angiotensin activating system) 
 Failure of clearance of inflammatory mediators 
- Retained solutes (cytokines and other mediators and glycated, oxidized  
  adducts) 
 Dysmetabolic states 
- Dyslipidemia 
- Central (visceral) obesity 
- Insulin resistance 
                                    In the clinical setting, the most commonly used 
biomarker of inflammation is C-Reactive Protein (CRP), one of the member 
of pentraxin family and the prototypic acute phase reactant. Other acute 
phase reactants include serum amyloid A, ferritin and fibrinogen. These 
proteins are the forward or positive acute phase reactants, whose serum 
levels increase during inflammation. The reverse or the negative acute 
phase reactants include albumin, prealbumin (transthyretin) and Fetuin-A 
and the level of these proteins fall during inflammation. 
                                   CRP, the prototypic inflammatory marker, inter 
leukin-6, and fibrinogen are the independent predictors of mortality in CKD 
patients. These markers have been attributed to their pro-atherogenic 
properties such as promotion of vascular calcification, oxidative stress and 
endothelial dysfunction. 
 
VASCULAR CALCIFICATION IN CKD: 
DISTURBANCES IN CALCIUM-PHOSPHORUS HOMEOSTASIS IN 
CKD:
44 
 Reduced GFR in CKD patients results in decreased excretion of 
phosphate, leading to severe hyperphosphatemia. 
 Impaired vitamin D synthesis in the body leads to hypocalcemia which 
is the trigger for excessive secretion of paratharmone leading onto 
secondary hyperparathyroidism. 
                              The disturbances in calcium-phosphorus homeostasis 
have been found to play a vital role in the pathogenesis of vascular 
calcification in CKD. 
TYPES OF VASCULAR CALCIFICATION:
45 
(I) Atherosclerotic/intimal calcification: 
- Occurs in the intimal layer and associated with plaques and occlusive 
lesions 
(II) Monkeberg sclerosis/medial calcification: 
- Involves circumferential deposition of amorphous mineral forms in the 
elastic lamellae of medial layer 
► Both types of vascular calcification are stimulated by CKD46. The 
hemodynamic consequences of vascular calcification like heart failure and 
myocardial infarction are the major causes of mortality in most of the patients 
with CKD. 
PATHOGENESIS:
47,48,49,50 
 Mesenchymal stem cells normally differentiate into chondrocytes, 
adipocytes, osteoblasts and vascular smooth muscle cells (VSMC). 
 In the setting of CKD, there is upregulation of transcription factors like 
Cbfa1/RUNX-2 and MSX-2 that are critical for bone development in 
vascular smooth muscle cells. The upregulation of these transcription 
factors in VSMC is indicative of a phenotypic switch that results in 
dedifferentiation of these cells into osteo/ chondrocytic- like cells. 
  This phenotypic transformation, lead onto the calcification of VSMC in 
a process similar to bone formation. These cells begin to lay down 
collagen and other noncollagenous proteins in the intima or media of the 
blood vessels (Figure 4). 
 Further the extremes of bone turnover prevailing in CKD, alters the 
calcium and phosphorus content of the bone which results in increased 
blood levels of these minerals. 
 Ultimately, whether an artery undergoes calcification or not depends on 
the strength of the army of circulating inhibitors like Fetuin-A and 
locally produced inhibitors like pyrophosphate and matrix-Gla protein. 
 
 
  
 
Fig.4: MECHANISMS OF VASCULAR CALCIFICATION IN CKD 
 
 
 
                
 
 
 
 
HYPERPHOSPHATEMIA IN CKD: 
                    Elevated levels of serum phosphorus are associated with an 
increased risk of cardiovascular disease among patients with CKD. The ability 
of the kidneys to control serum phosphate levels becomes impaired at GFR 
~50-60 ml/min
53
. 
                              The following mechanisms may be responsible for the 
pathogenic cardiovascular effects of hyperphosphatemia (Figure 5). 
 Hyperphosphatemia directly causes vascular injury by promoting 
vascular calcification and increasing the reactive oxygen species.  
 Indirectly, it increases the serum levels of paratharmone and fibroblast 
growth factor-23.  
 Hyperphosphatemia may also promote or facilitate inflammation in 
patients with CKD. Since phosphorylation events regulate the important 
steps of inflammatory pathways, the increased serum phosphate levels 
may trigger phosphorylation-driven signaling inflammatory cascade
54,55
.                            
 
 
 
 
 
Figure 5: HYPERPHOSPHATEMIA IN CKD 
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                    In appreciation of the wider consequences of disturbed mineral 
and bone metabolism in patients with CKD, a new nomenclature – “CKD-
MBD” (mineral-bone disorder) has been introduced by the Kidney Disease 
Improving Global Outcomes (KDIGO), 2006 to describe this broader 
clinical syndrome. 
DEFINITION OF CKD-MBD:
51,52 
                           A systemic disorder of mineral and bone metabolism due to 
CKD is manifested by either one or a combination of the following: 
 Abnormalities of calcium, phosphorus, paratharmone and vitamin D 
metabolism 
 Abnormalities in bone turn over, mineralization, volume, linear growth 
or strength 
 Vascular or other soft tissue calcification 
 
 
 
 
 
 
 
FETUIN-A / α2–HEREMANS-SCHMID GLYCOPROTEIN (AHSG): 
                       The serum protein Fetuin was initially identified as the major 
globulin in calf and fetal serum by Pedersen in 1944. The human homologue 
was named Fetuin-A/α2–Heremans-Schmid glycoprotein (AHSG), after the two 
co-discoverers, Heremans and Schmid. A closely related protein, Fetuin-B also 
exists in human, rat and mouse genomes
56
.  
                       During fetal development, Fetuin-A is expressed in most organs 
including liver, kidney, gastrointestinal tract, skin and brain. In adults, it is 
produced primarily by the liver. The serum Fetuin-A concentration of adult 
humans ranges from 0.5-1 g/L
57,78
. 
STRUCTURE: 
                       Fetuin-A, a 59 kDa glycoprotein, belong to the cystatin 
superfamily of cysteine protease inhibitors. It contains 3 domains- D1, D2, D3. 
D1 and D2 are cystatin like domains located in the amino terminal region. 
Domain 3 forms the C-terminal part of Fetuin-A and it is rich in proline 
(collagen like domain)
58
. 
                       Fetuin-A is composed of 2 subunits- the heavy ‘A’ chain and the 
light ‘B’ chain. ‘A’ chain consists of 282 aminoacid residues while ‘B’ chain 
consists of 27 residues. A disulfide bridge between cys-14 and cys-340 joins 
both the chains. There are also 5 intra chain disulfide bridges in the ‘A’ chain.  
 
                                        Figure 6:  STRUCTURE OF FETUIN-A 
                                                            
                                                      
 
 
                                         Figure 7: FETUIN-A GENE 
                                                               
                                                                        
 
 
                        Fetuin-A has a binding site for calcium-phosphate near the N-
terminus. A TGF-β cytokine binding motif is present from cys-96 to cys-114 in 
the N-terminal cystatin domain. This motif has sequences similar to that of the 
extracellular domain of TGF-β receptor type II 59. 
                     The molecule also has interesting and unique features:
60 
 In circulating Fetuin-A, there are 29 aminoacid doublets in which Ala-
Ala and Pro-Pro sequences get repeated 6 times. 
 Fetuin-A also contains collagen-like sequences that are found in the 
complement component C1q. 
SYNTHESIS: 
                      Fetuin-A is mainly synthesized by the hepatic parenchymal cells. 
The human gene was mapped to the region 3q21-29 of chromosome 3. The 
mode of inheritance is autosomal dominant
61
. 
 Fetuin-A is a typical secretory protein, biosynthesized from a single 
mRNA transcript in the form of a precursor protein of 367 aminoacid 
residues. 
 Pre-Fetuin-A comprises a transient signal sequence of 18 residues, 
followed by the sequence of ‘A’ chain (positions 1-282 of matured 
protein), a connecting peptide (positions 283-322) and the ‘B’ chain 
(position 323-349).  
 In a post translational step, the connecting peptide is cleaved by limited 
proteolysis which produces ‘A’ and ‘B’ chains that are joined together 
by a disulfide bond
62
. 
 Fetuin-A is also post translationally modified by the addition of five 
carbohydrate side chains – three of them are attached via O-glycosidical 
and two via N-glycosidical linkages. Fetuin-A is also phosphorylated at 
serine residues, particularly on serine-120 located in the ‘A’ chain and 
on serine-312 located in the connecting peptide
63
. 
                       Figure 8 shows the post-translational modification of 
Fetuin-A. Black wedges indicate proteolytic cleavage sites, red asterisks 
indicate serine phosphorylation sites, large green beacons indicate N-
glycosylation sites and small green beacons indicate O-glycosylation 
sites. Binding regions for apatite and TGF-β like growth factors are 
shown as pink triangles.  
Fig.8: POST-TRANSLATIONAL MODIFICATION OF FETUIN-A 
              
 
 
BIOLOGICAL FUNCTIONS OF FETUIN-A: 
                        A wide range of biological functions have been proposed for     
Fetuin-A. 
(i) OSTEOGENESIS:64,65 
 Fetuin-A is one of the most abundant non-collgenous protein 
found in the bone. The concentration of Fetuin-A present in 
one gram of bone is ~ 1 mg. It binds strongly to apatite which 
is the mineral phase of the bone and is concentrated 
selectively from the serum to the apatite. Further 
mineralization of type I collagen fibrils is promoted by  
Fetuin-A. 
 Fetuin-A is concentrated up to 300 fold in the matrix of adult 
and fetal bone compared to other glycoproteins. Fetuin-A 
concentration progressively decreases in bone throughout 
childhood to adult life. 
 Fetal bone was found to contain atleast 10 times more Fetuin-
A than the adult bone, while neonatal bone contains 7 times 
more Fetuin-A than does the adult bone. The reasons for low 
concentrations of serum Fetuin-A in adulthood may be,  
 Bone mineralization starts in utero and rapid bone growth and 
mineralization occur soon after birth. During this time, Fetuin-A may be 
needed critically as a mineral chaperone to overcome pathological 
mineralization and also to help in physiologic bone mineralization. This 
results in selective concentration of Fetuin-A from serum to the apatite 
in bone, thereby reducing its serum concentration. 
(ii)  INHIBITION OF PATHOLOGICAL CALCIFICATION:66,67 
 Fetuin-A is a systemic protein inhibitor of calcification and is 
present throughout the extra cellular space.  
 ~ 50% of calcification inhibitory capacity of the human 
plasma is contributed by Fetuin-A. 
 Formation of fetuin-mineral complex inhibits the precipitation 
of basic calcium phosphate (BCP), thereby preventing 
unwanted calcification. 
 One Fetuin-A molecule can bind six calcium ions. BCP 
precipitation inhibition activity resides in the cystatin-like 
domain D1 of Fetuin-A. This domain harbors an EF-hand-like 
Ca
2+
 binding motif. 
MECHANISM OF INHIBITION: 
 In the serum, Fetuin-A stabilizes calcium and phosphate and prevents 
their precipitation by binding BCP. In this process, it forms transiently 
soluble, colloidal complexes called calciprotein particles, which are 30-
150nm in diameter. Fetuin-A coating of BCP nuclei will delay the 
growth of insoluble crystals which in turn favours mobilization and 
removal of insoluble calcium salts in the calciprotein particles by 
phagocytosis
68
.  
                   
                                   Figure 9: CALCIPROTEIN PARTICLE (CPP) 
 
                                               
 
 
 Figure 10: DOMAIN D1 OF FETUIN-A BINDING HYDROXYAPATITE 
 
                                              
 
                   Figure 9 shows the hypothetical model of a calciprotein 
particle (large sphere quadrant) containing upto 100 globular Fetuin-A 
molecules (small spheres) with domain D1 bound to the apatite. Figure 
10 shows Fetuin-A domain D1 (top) bound to the apatite crystals 
(bottom). Surface binding of calcium is mediated by the negative 
charges on the extended β sheet of the D1 domain resulting in high 
affinity binding despite the relatively low serum concentration of 
Fetuin-A.                 
                   Fetuin-A thus acts as a systemic inhibitor of pathological 
mineralization which complement the local inhibitors like matrix-Gla 
protein and pyrophosphate that act in a cell-restricted/ tissue-restricted 
fashion
69
.   
(iii) INHIBITION OF INFLAMMATION:70,71 
         Fetuin-A is an anti-inflammatory protein that can attenuate the 
inflammatory responses by the following mechanisms: 
 Fetuin-A participates in macrophage deactivation. It enhances 
the uptake of pro-inflammatory cytokine synthesis inhibitors 
by macrophages, thereby preventing the morbid sequelae that 
would result from over production of pro-inflammatory 
cytokines.  
 Spermine accumulates at the sites of inflammation and it 
inhibits the synthesis of cytokines by macrophages only in the 
presence of Fetuin-A. 
 Fetuin-A also plays a role in mediating innate immunity. 
 But the expression of Fetuin-A is negatively regulated by several pro-
inflammatory cytokines which produces down regulation of its 
synthesis during inflammation; hence Fetuin-A is regarded as a 
“negative acute phase reactant”. 
(iv) OPSONIZATION:73 
                    Fetuin-A also acts as an opsonin. It quenches the 
oxidative burst that occurs during the uptake of apatite crystals by 
neutrophils. It also facilitates marking and elimination of apoptotic 
neutrophils. 
(v) INHIBITION OF INSULIN SIGNALLING: 
                    Fetuin-A binds to the insulin receptor and inactivate the 
tyrosine kinase. Fetuin-A thereby inhibits the insulin-stimulated 
autophosphorylation of the insulin receptor and is associated with 
insulin resistance
72
.   
(vi) INHIBITION OF TGF-β SIGNALING:74 
                     The aminoacid sequence of Fetuin-A is similar to that 
of TGF-β receptor. Hence Fetuin-A binds to TGF-β and prevents it 
from binding to its receptors thereby antagonizing TGF-β mediated 
anti-proliferative effects. 
 
 
 
                                     AIMS AND OBJECTIVES 
 
AIM: 
          To estimate the levels of serum Fetuin-A in patients with CKD and to 
compare them with healthy controls. 
OBJECTIVES: 
1. To study the relationship of serum Fetuin-A with the inflammatory 
biomarkers, hsCRP and albumin 
2. To evaluate the association of serum Fetuin-A with creatinine clearance 
3. To find out the correlation of serum Fetuin-A with calcium-phosphorus 
levels and lipid profile   
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
                       The study was conducted at Thanjavur Medical College hospital, 
Thanjavur after getting approval from the ethical committee.  
                       80 patients (55 males and 25 females) were selected as cases 
from the outpatients and wards of the department of Nephrology. 80 age and 
gender matched healthy individuals were selected as controls. 
INCLUSION CRITERIA: 
- Patients with established diagnosis of CKD  
- Age > 18 years 
EXCLUSION CRITERIA:  
- Acute/Chronic inflammatory diseases 
- Previous history of cerebrovascular diseases 
- Patients who underwent renal transplant 
- Acute kidney injury 
- Nephrotic syndrome 
- Patients on lipid lowering drugs and calcium/phosphate binders 
- Malignancy 
- Patients on immunotherapy/immunosuppressive treatment 
                       Informed consent was obtained from all subjects prior to the 
study. Blood samples were collected from them after an overnight fasting of 12 
hours. Under aseptic precautions, 5 ml of venous blood sample was collected 
from each patient. After retraction of the clot, the samples were centrifuged at 
2000 rpm for 15 minutes for separation of serum.  
                        An aliquot of the serum was taken for the estimation of Fetuin-
A and stored at -20
◦
C in the deep freezer. The remaining serum was used for 
estimation of glucose, urea, creatinine, calcium, phosphorus, hsCRP, albumin, 
total cholesterol, triglycerides and HDL-C.                   
ANALYSIS OF BLOOD SAMPLES: 
The serum collected above was used for the estimation of the following 
parameters. 
A. ESTIMATED PARAMETERS: 
1. Fetuin-A – Enzyme immunoassay 
2. hsCRP – Turbidimetric immunoassay 
3. Urea – Urease (GLDH) method 
4. Creatinine – Modified Jaffe’s method 
5. Albumin - BromoCresol Green dye binding method   
6. Calcium – Arsenazo method 
7. Phosphorus – UV Molybdate method 
8. Total cholesterol – Cholesterol-Oxidase – PAP method 
9. Triglycerides – GPO – PAP method 
10. HDL-C – Phosphotungstate/Magnesium precipitation method 
11. Glucose – Glucose-Oxidase/Peroxidase method 
 
B. CALCULATED PARAMETERS: 
1. LDL-C and VLDL-C were calculated using Friedwald’s formula: 
VLDL-C = TGL/5 
 LDL-C = TC – [HDL-C + (TGL/5)] 
2. Creatinine clearance (Ccr) was calculated using Cockcroft-Gault 
formula: 
(mg/dl) NES.CREATINI * 72
(Kg)  WEIGHT* (Years)] AGE - [140
 C cr  
For females,  
85.0*
(mg/dl) NES.CREATINI * 72
(Kg)  WEIGHT* (Years)] AGE - [140
 C cr  
3. Calcium-phosphorus product (Ca X P) was calculated by multiplying 
the serum calcium and phosphorus values. 
 
            
 
 
 
 
 
 
 
ESTIMATION OF SERUM FETUIN-A:  
                           Enzyme linked immunosorbent assay (ELISA) kit obtained 
from R&D systems was used. 
PRINCIPLE OF THE ASSAY: 
                           Quantitative sandwich enzyme immunoassay technique is 
employed. A monoclonal antibody specific for Fetuin-A has been pre-coated 
onto a microplate. Standards and samples are pipetted into the wells and any 
Fetuin-A present is bound by the immobilized antibody. An enzyme-linked 
monoclonal antibody specific for Fetuin-A is added to the wells after washing 
away any unbound substances. Following a wash to remove any unbound 
antibody-enzyme reagent, a substrate solution is added to the wells and colour 
develops in proportion to the amount of Fetuin-A bound. The colour 
development is stopped and the intensity of the colour is measured. 
MATERIALS PROVIDED IN THE KIT: 
1. Fetuin-A microplate: 96 well polystyrene microplate coated with a 
mouse monoclonal antibody against Fetuin-A 
2. Fetuin-A standard: 1000 ng of recombinant human Fetuin-A in a 
buffered protein base with preservative; lyophilized 
3. Fetuin-A conjugate: 21 ml of a monoclonal antibody against Fetuin-A 
conjugated to horseradish peroxidase with preservatives 
4. Calibrator diluent RD5-26 concentrate: 21 ml of a concentrated buffered 
protein base with preservatives 
5. Assay diluent RD1X: 11 ml of a buffered protein base with preservative 
6. Wash buffer concentrate: 21 ml of a 25-fold concentrated solution of 
buffered surfactant with preservative 
7. Colour Reagent A: 12.5 ml of stabilised hydrogen peroxide 
8. Colour Reagent B: 12.5 ml of stabilized chromogen (tetramethyl 
benzidine) 
9. Stop solution: 6 ml of 2 N sulphuric acid 
SAMPLE PREPARATION: 
                      Samples require a 4000-fold dilution. 10µL of the sample was 
added to 990 µL of the Calibrator Diluent RD5-26 (1X) and 25 µL of this 
diluted sample was added to 975 µL Calibrator Diluent RD5-26 (1X) to get a 
4000-fold dilution. 
REAGENT PREPARATION: 
                     All the reagents were brought to room temperature before use. 
Wash buffer: 20 ml of wash buffer concentrate was diluted into distilled water 
to prepare 500 ml of wash buffer. 
Substrate solution: Colour reagents A and B were mixed together in equal 
volumes within 15 minutes of use and protected from light. 
Calibrator Diluent RD5-26 (IX): 5 ml of Calibrator Diluent RD5-26 was 
diluted into 45 ml of distilled water to prepare 50 ml of Calibrator Diluent 
RD5-26 (IX). 
Fetuin-A standard: 
                               Fetuin-A standard was reconstituted with 2 ml of calibrator 
diluent RD5-26(IX), which produces a stock solution of 500 ng/ml. A dilution 
series was produced as follows: 
STANDARD 
TUBES 
CALIBRATOR 
DILUENT RD5-26(IX) 
AMOUNT OF 
FETUIN-A 
STANDARD (µl) 
CONCENTRATION 
OF FETUIN-A 
STANDARD(ng/ml) 
1 250 µl - 0 
2 250 µl 250 µl of tube no. 3 7.8 
3 250 µl 250 µl of tube no. 4 15.6 
4 250 µl 250 µl of tube no. 5 31.3 
5 250 µl 250 µl of tube no. 6 62.5 
6 250 µl 250 µl of tube no. 7 125 
7 250 µl 250 µl of stock 250 
8 - 250 µl of stock 500 
  
ASSAY PROCEDURE: 
1. 100 µL Assay Diluent RD1X was added to each well 
2. 50 µL of standard and sample was then added to each well and 
incubated for 2 hours at each temperature. Wells were aspirated and 
washed 4 times 
3. 200 µL conjugate was added to each well and incubated for 2 hours at 
room temperature. Wells were aspirated and washed 4 times 
4. 200 µL substrate solution was added to each well and incubated for 30 
minutes at room temperature and protected from light 
5. 50 µL of stop solution was added to each well and read at 450 nm within 
30 minutes 
CALIBRATION GRAPH: 
                     By plotting the mean absorbance for each of the standards on the 
y-axis against the concentration of Fetuin-A on the x-axis, a calibration graph 
was constructed (Figure 11). 
Figure 11: STANDARD GRAPH FOR FETUIN-A 
                           
 
SENSITIVITY: 
                        The minimum detectable dose of Fetuin-A was 0.16-1.74 ng/ml. 
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ESTIMATION OF SERUM hs-CRP: 
METHOD: Turbidimetric immunoassay (Biosystems)  
PRINCIPLE: 
                       Serum C-reactive protein (CRP) causes agglutination of the latex 
particles coated with anti-human C-reactive protein. The latex agglutination is 
proportional to the concentration of CRP and can be measured by turbidimetry. 
REAGENTS REQUIRED: 
1. REAGENT A: Glycine buffer 0.1mol/L, sodium azide 0.95 g/L, pH 8.6 
2. REAGENT B: Suspension of latex particles coated with anti-human 
CRP antibodies, sodium azide 0.95 g/L 
3. hsCRP standard: 13.8 mg/L 
REAGENT PREPARATION: 
 Working reagent: Reagent B was poured into reagent A vial and mixed. 
  hsCRP standard:  
                            hsCRP standard was reconstituted with 5 ml of 
distilled water which produces a stock solution of 13.8 mg/L. A dilution 
series was prepared as follows:  
 
 
STANDARD 
TUBES 
NORMAL 
SALINE 
AMOUNT OF 
hsCRP 
STANDARD (µl) 
CONCENTRATION 
OF hsCRP 
STANDARD (mg/L) 
1 100 µl  - 0 
2 100 µl 100µl of tube no. 3 0.43 
3 100 µl 100 µl of tube no. 4               0.86 
4 100 µl 100 µl of tube no. 5 1.725 
5 100 µl 100 µl of tube no. 6 3.45 
6 100 µl 100 µl of stock 6.9 
7 - 100 µl of stock 13.8 
 
PROCEDURE: 
                Reagents and samples were brought to room temperature prior to use. 
1) Zero correction of the instrument was done with distilled water. 
2)  Working reagent 1.5 ml and serum 20 µl were mixed in a cuvette.  
3) Immediately the cuvette was inserted into the instrument and stop watch 
started.  
4) The absorbance was recorded at 540 nm after 10 seconds (A1) and after 
5 minutes (A2) 
CALIBRATION: 
                  The absorbance difference (A2 - A1) of each point of the calibration 
curve was calculated and the values found were plotted against the hsCRP 
concentration and the calibration graph was constructed (Figure 12). The 
hsCRP concentration in the sample was calculated by interpolation of its 
absorbance (A2 - A1) on the calibration curve.  
                  Figure 12: STANDARD GRAPH FOR hsCRP 
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ESTIMATION OF UREA: 
METHOD: Urease-GLDH method 
PRINCIPLE: 
                     Urea in the sample is hydrolysed to ammonia and carbon di oxide 
by urease. Glutamate dehydrogenase (GLDH) catalyse the second reaction that 
converts ammonia and α-ketoglutarate to glutamate and water with the 
concurrent oxidation of reduced NADH to NAD. Two moles of NADH are 
oxidized for each mole of urea present. 
                Urea + H2O                         2NH4
+
 + CO2 
NH4
+
 + NADH + H
+
 + 2-Oxoglutarate                     Glutamate + NAD
+
  
The initial rate of decrease in absorbance at 340 nm is proportional to the urea 
concentration in the sample. 
REAGENT COMPOSITION: 
Reagent 1: α-ketoglutaric acid 99.8 mmol/L, Urease 23.5 KU/L, GLDH 3.5 
KU/L,     Adenosine diphosphate 7.6 mmol/L, Sodium azide 0.2% 
Reagent 2: NADH 2.95 mmol/L, Sodium azide 0.1% 
REAGENT PREPARATION: 
Working reagent was prepared by mixing 4 parts of reagent 1 with one part of 
reagent 2. 
Urease 
 GLDH 
 
PROCEDURE: 
PIPETTE INTO 
TUBES 
BLANK STANDARD TEST 
Working Reagent 1000 µl 1000 µl 1000 µl 
Standard - 10 µl - 
Test - - 10 µl 
 
The tubes were mixed well and the absorbance was read after 30 seconds (A1) 
and 60 sec (A2) at 340 nm. 
CALCULATION: 
∆A = A2 – A1 
mg/dl) (50 standard ofion Concentratx 
  standard ofA 
 testofA 
 (mg/dl)  Urea


  
LINEARITY: The method is linear upto 200 mg/dl 
REFERENCE INTERVAL: 15-30 mg/dl  
 
ESTIMATION OF SERUM CREATININE: 
METHOD:  
                    Modified Jaffe’s method 
 
PRINCIPLE: 
                       Creatinine reacts with alkaline picrate to produce an orange-
yellow colour. The intensity of the orange-yellow colour formed is directly 
proportional to concentration of creatinine and is measured photometrically at 
500-520 nm. 
REAGENT COMPOSITION: 
REAGENT NO. COMPOSITION CONCENTRATION 
1 Picric acid 25.8 mmol/L 
2 Sodium hydroxide 95 mmol/L 
 
CREATININE STANDARD: 2 mg/dl 
REAGENT PREPARATION: Equal volumes of reagent 1 and reagent 2 were 
mixed and waited for 15 minutes before use. 
PROCEDURE: 
PIPETTE STANDARD TEST 
Working Reagent 1000 µl 1000 µl 
Standard 100 µl - 
Test - 100 µl 
The tubes were mixed well and the initial absorbance A1 [20 seconds after 
mixing] and final absorbance A2 [80 seconds after mixing] were read at 505 
nm. 
CALCULATION: 
∆A = A2 – A1  
(mg/dl) standard ofion Concentratx 
  standard ofA 
 testofA 
 (mg/dl)Creatinine Serum


  
LINEARITY: The assay is linear upto 20 mg/dl 
REFERENCE RANGE: 
Males: 0.7-1.4 mg/dl 
Females: 0.6-1.2 mg/dl 
 
ESTIMATION OF SERUM ALBUMIN: 
METHOD:  
                       BromoCresol Green dye binding method 
PRINCIPLE: 
                       Albumin at pH 4.2, binds with BromoCresol Green (BCG) which 
causes a shift in absorbance of the yellow BCG dye. The blue-green colour 
formed is measured photometrically between 580-630 nm with maximum 
absorbance at 625 nm and is proportional to the albumin concentration.  
 
 
REAGENT COMPOSITION: 
BromoCresol Green 0.08 mmol/L 
Succinate buffer (pH 
4.2 ± 0.1 at 25
◦
 C) 
50 mmol/L 
Sodium azide 1 gm/L 
 
Albumin Standard: 3.6 g/dl  
PROCEDURE: 
 
 
 
 
 
The tubes were mixed well and the absorbance of standard and test were read at 
630 nm (580-630 nm) against reagent blank after 1 minute incubation at 37
◦
 C. 
CALCULATION: 
(g/dl) standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
 (g/dl)Albumin  Serum    
LINEARITY: The assay is linear upto 6 g/dl. 
NORMAL VALUE: 3.5-5 g/dl 
PIPETTE INTO 
TUBES MARKED 
BLANK STANDARD TEST 
Albumin reagent 1000 µl 1000 µl 1000 µl 
Distilled water 10 µl - - 
Standard - 10 µl - 
Test - - 10 µl 
ESTIMATION OF SERUM CALCIUM: 
METHOD: Arsenazo method 
PRINCIPLE: 
                     Arsenazo III combines with calcium ions at pH 6.5 to form a 
coloured chromophore, the absorbance of which is measured at 650 nm and is 
proportional to calcium concentration.  
REAGENT COMPOSITION: 
ACTIVE INGREDIENTS CONCENTRATION 
Arsenazo III 0.20 mmol/l 
Imidazole buffer (pH 6.5±0.1) 100 mmol/l 
 
Calcium standard: 10 mg/dl 
PROCEDURE: 
 
 
 
 
 
PIPETTE INTO 
TUBES MARKED 
BLANK STANDARD TEST 
Calcium reagent 1000 µl 1000 µl 1000 µl 
Distilled water 10 µl - - 
Standard - 10 µl - 
Test - - 10 µl 
The tubes were mixed well, incubated at 37
◦
 C for 5 minutes and the 
absorbances were measured at 540 nm. 
CALCULATION: 
10x 
  standard of Absorbance
 testof Absorbance
 (mg/dl) Calcium Serum   
LINEARITY: The assay is linear upto 16 mg/dl 
REFERENCE RANGE: 9-11 mg/dl 
 
ESTIMATION OF SERUM PHOSPHORUS: 
METHOD: UV Molybdate method 
PRINCIPLE: 
                    Inorganic phosphorus reacts with ammonium molybdate in acidic 
medium to form phosphomolybdate complex. This colourless complex is 
measured at 340 nm and is directly proportional to the inorganic phosphorus 
concentration in the sample. 
 
 
 
 
REAGENT COMPOSITION: 
REAGENT NO. REAGENT COMPOSITION CONCENTRATION 
1 Molybdate 
reagent 
Ammonium Molybdate 
Surfactant 
0.3 mM/L 
2 Sample blank 
reagent 
Sodium chloride 
Preservative 
154 mM/L 
3 Phosphorus 
Standard 
Potassium dihydrogen 
phosphate 
5 mg/dl 
 
PROCEDURE: 
PIPETTE INTO 
TUBES MARKED 
REAGENT 
BLANK 
STANDARD TEST 
Serum - - 10 µl 
Reagent 3 - 10 µl - 
Reagent 1 1000 µl 1000 µl 1000 µl 
 
The tubes were mixed well and incubated at 37
◦
 C for 5 minutes. After 
blanking the analyser with reagent blank, the absorbances were measured at 
340 nm. 
CALCULATION: 
5x 
  standard of Absorbance
 testof Absorbance
 (mg/dl) Phosphorus Serum   
REFERENCE RANGE: 
2.5-4.5 mg/dl 
 
TOTAL CHOLESTEROL ESTIMATION 
METHOD: Cholesterol oxidase - PAP, endpoint 
PRINCIPLE:    
1. Cholesterol ester +Water                                 Cholesterol + Fatty acid 
2. Cholesterol + Oxygen                                Cholest-4-en-3one + H2O2 
3. 2H2O2 + 4AAP+ Phenol                               Quinoneimine dye + 4H2O 
 4AAP- 4 amino antipyrine 
 Absorbance of quinoneimine formed is directly proportional to 
cholesterol concentration. 
 Cholesterol standard – 200mg/dl 
 Sample:  Unhemolysed serum  
 
REAGENT COMPOSITION: 
Goods buffer (pH-6.4) :  100mmol/L 
Cholesterol oxidase    :  >100U/L 
Cholesterol esterase     :  >200U/L 
Cholesterol oxidase 
 Peroxidase 
 
 Cholesterol esterase  
 
Peroxidase                   :  >3000U/L 
4-Aminoantipyrine     : 0.3mmol/L 
Phenol                         :  5mmol/L 
PROCEDURE: 
REAGENTS BLANK STANDARD TEST 
Working reagent 1000 µl 1000 µl 1000 µl 
Distilled water 10 µl - - 
Standard - 10 µl - 
Sample - - 10 µl 
 
 The tubes were mixed well and incubated for 10 min at room 
temperature. The absorbance of the test and standard were read against reagent 
blank at wavelength of 505 nm. 
CALCULATION: 
(mg/dl) standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
 (mg/dl) lCholestero   
 
 
 
REFERENCE RANGE: 
SERUM/PLASMA mg/dl 
2-12 months 60-190 
≥ 1 year 110-230 
Adults < 200 
 
Linearity-upto 700mg/dl 
 
ESTIMATION OF TRIGLYCERIDES: 
METHOD: 
                      Colorimetric, enzymatic method with glycerol phosphate oxidase 
(GPO-PAP method).This reagent is based on the method of Wako and the 
modifications by McGowan et al. and Fossati et al. 
PRINCIPLE: 
Triglycerides + H2O                    Glycerol + free fatty acids 
Glycerol + ATP                     Glycerol 3 phosphate + ADP 
Glycerol 3 phosphate + O2                      DAP + H2O2 
H2O2 + 4AAP + 3, 5-DHBS                             Quinoneimine dye+2H2O 
Lipoprotein lipase 
Glycerol kinase 
Glycerol Phosphate Oxidase 
Mg
2+
 
Peroxidase 
ATP - Adenosine Tri Phosphate, 4AAP - 4Amino Anti Pyrine, DHBS - 3, 5 
Dichloro-2Hydroxy Benzene Sulfonate 
The intensity of Quinoneimine dye formed is proportional to the 
triglyceride concentration in the sample when measured at 505 nm (500-
540nm). 
Triglycerides standard concentration- 200mg/dl 
REAGENT COMPOSITION: 
REAGENT 1(Enzymes / Chromogen): 
 
 
 
 
 
 
REAGENT 2: 
Pipes buffer, pH-7.0:  40mmol/L 
DHBS: 0.2mmol/L 
Magnesium salt: 2.5mmol/L 
Lipoprotein lipase 4000 U/L 
4-Amino antipyrine 0.4 mmol/L 
ATP 2mmol/L 
Glycerol kinase 1500 U/L 
Peroxidase 2200 U/L 
Glycerol Phosphate Oxidase 4000 U/L 
WORKING REAGENT PREPARATION: 
The working reagent was prepared by mixing 4 parts of R1 with 1 part 
of R2, stable for 90 days at 2-8
◦
C. 
PROCEDURE: 
REAGENTS BLANK STANDARD TEST 
Working reagent 1000µl 1000 µl 1000 µl 
Distilled water 10 µl - - 
Standard - 10 µl - 
Sample - - 10 µl 
 
Mixed and incubated for 10min. Absorbance read at 505nm for standard 
and sample against reagent blank. 
CALCULATION: 
(mg/dl) standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
  (mg/dl) desTriglyceri 
 
REFERENCE VALUES: 25-160 mg/dl 
LINEARITY: upto 1000mg/dl 
 
 
HDL CHOLESTEROL ESTIMATION: 
METHOD: Phosphotungstic acid/Magnesium precipitation method, endpoint 
PRINCIPLE: 
Chylomicrons, VLDL-C and LDL-C are precipitated from the serum by 
phospho tungstate in the presence of divalent cations such as Magnesium. The 
HDL cholesterol reminds unaffected in the supernatant and is estimated using 
cholesterol reagent. 
 
Serum/plasma                                HDL-C + (LDL-C+VLDL-C+Chylomicrons)
           (supernatant)                  (Precipitate) 
 
REAGENT COMPOSITION: 
Reagent1: Precipitating reagent 
Phosphotungstic acid 2.4mmol/l 
Magnesium chloride 40mmol/l 
 
HDL cholesterol standard – 25mg/dl 
PRECIPITATION: 
Precipitation of LDL-C, VLDL-C and Chylomicrons were done as 
follows: 
Phosphotungstic acid 
Mg
2+
 
           Pipette  Volume 
Test 250µl 
Precipitating reagent 500 µl 
 
The tubes were mixed well and the reaction mixture was allowed to 
stand for 10 min at room temperature, centrifuged at 4000 rpm for 10 min and a 
clear supernatant was obtained. The supernatant was used to determine the 
concentration of HDL cholesterol in the sample. 
PROCEDURE: 
 
 
Mixed well and incubated for 10 min at room temperature. The 
absorbance of the standard and the test samples were read at 505 nm against 
reagent blank. 
Calculation: 
factordilution standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
  l(mg/dl)cholestero HDL 
 
REAGENTS BLANK STANDARD TEST 
Cholesterol 
working reagent 
1000µl 1000 µl 1000µl 
Distilled water 50 µl - - 
HDL standard - 50 µl - 
Supernatant - - 50 µl 
    =
  standard of Absorbance  
 testof Absorbance
  x 25 x 3 
LINEARITY: - upto 125mg/dl 
NORMAL VALUES:  
Males     - 30 to 65mg/dl 
Females – 35 to 80mg/dl 
 
ESTIMATION OF GLUCOSE 
METHOD: Trinder’s method, end point/fixed time 
PRINCIPLE: 
                        Glucose in the sample is oxidized to yield gluconic acid and 
hydrogen peroxide in the presence of glucose oxidase. The enzyme peroxidase 
catalyses oxidative coupling of 4 –amino antipyrine  (4-AAP)with phenol to 
yield a colored quinoneimine complex, with absorbance proportional to 
concentration of glucose in the sample. 
           Glucose + O2 + H2O                            Gluconic acid + H2O2 
       H2O2 + Phenol+4 AAP                            Quinoneimine dye + 2 H2O2 
Glucose standard: 100mg/dl 
Specimen: Fresh unhemolysed serum used 
Glucose Oxidase 
Peroxidase
e 
 
ASSAY PROCEDURE: 
REAGENTS BLANK STANDARD TEST 
Sample - - 10µl 
Standard - 10µl - 
Distilled water 10µl - - 
Enzyme reagent 1ml 1ml 1ml 
 
                 The tubes were mixed well after each addition and incubated at 37
◦
C 
for 5 min. The absorbance was read at 505nm/670nm. 
CALCULATION: 
 (mg/dl)  standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
  (mg/dl) GLUCOSE   
Linearity: upto 500mg/dl by endpoint method. 
NORMAL VALUES:   Glucose (Fasting): 65-110 mg/dl 
                                       Glucose (Postprandial): 90-140mg/dl 
 
 
 
RESULTS AND STATISTICAL ANALYSIS: 
S.No 
AGE 
years SEX 
HT 
m 
WT 
Kg 
BMI 
Kg2/m2
 
SBP 
mmHg 
DBP 
mmHg 
FBG 
mg/dl 
UREA 
mg/dl 
CREAT 
mg/dl 
Ccr 
ml/min 
hsCRP 
mg/L 
FETUIN-A 
g/L 
CAL 
mg/dl 
PHOS 
mg/dl 
CaXP 
mg2/dl2
 
ALB 
g/dl 
TC 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
VLDL 
mg/dl 
LDL 
mg/dl 
1 38 M 1.68 62 21.97 110 70 86 20 0.9 97.59 0.83 0.58 9.6 3.04 29.18 3.8 168 110 42 22 104 
2 31 M 1.64 68 25.28 104 80 90 22 1.1 93.59 0.29 0.618 10.2 2.67 27.23 3.67 186 150 46 30 110 
3 37 M 1.6 72 28.13 120 76 80 18 0.9 114.4 0.21 0.734 9.4 4.1 38.54 4.25 164 122 46 24.4 93.6 
4 35 M 1.56 66 27.12 90 70 98 28 0.9 106.9 0.58 0.853 10.6 2.93 31.06 4.05 150 112 45 22.4 82.6 
5 37 M 1.7 70 23.53 110 80 100 20 1.1 91.04 0.81 0.612 10.9 3.52 38.37 3.64 180 135 42 27 111 
6 26 M 1.68 68 24.09 114 76 102 24 0.8 134.6 0.46 0.528 9.87 3.15 31.09 4 174 140 40 28 106 
7 32 M 1.7 65 22.49 100 70 78 24 0.8 121.9 0.89 0.59 10.4 3.6 37.26 4.5 150 124 38 24.8 87.2 
8 33 M 1.56 67 27.53 96 80 82 18 0.9 110.6 0.33 0.606 10.9 3.28 35.75 3.74 160 150 46 30 84 
9 35 M 1.56 55 22.6 112 80 96 26 0.8 100.3 0.42 1.13 10.5 2.97 31.19 4.65 176 142 42 28.4 106 
10 34 M 1.62 68 25.91 98 74 72 20 1 100.1 0.22 0.71 9.6 3.8 36.48 3.58 178 135 50 27 101 
11 36 M 1.65 60 20.57 120 80 78 20 0.9 96.3 0.56 0.52 10.3 2.83 29.15 3.96 184 140 40 28 116 
12 38 M 1.68 67 23.74 116 76 100 22 1 94.92 0.92 0.56 9.2 4.3 39.56 4.04 160 138 45 27.6 87.4 
13 36 M 1.56 65 26.71 90 70 104 28 1 93.89 0.81 0.819 10.6 2.82 29.89 4 208 122 41 24.4 143 
14 28 M 1.65 56 20.57 118 80 84 20 0.9 96.79 0.67 0.72 9.37 3.26 30.55 3.68 188 120 40 24 124 
15 58 M 1.69 68 23.81 110 78 90 26 0.8 96.81 0.72 0.618 10.5 3.7 38.85 3.9 175 154 48 30.8 96.2 
16 68 M 1.68 73 25.86 100 70 86 26 0.8 91.25 0.32 0.63 10.3 3.15 32.45 4.2 182 160 44 32 106 
17 64 M 1.58 69 27.64 96 76 92 24 0.8 91.04 0.88 0.59 9.5 4.2 39.9 4.24 168 110 42 22 104 
18 61 M 1.63 60 19.2 126 74 76 24 0.7 94.05 0.41 0.614 9.23 3.5 32.31 4.13 200 124 45 24.8 130 
19 62 M 1.67 68 24.38 90 70 84 28 0.8 92.08 0.29 0.597 10.5 3.27 34.34 3.7 165 115 42 23 100 
20 53 M 1.7 68 23.53 108 72 98 22 0.9 91.3 0.47 0.508 10.7 3.25 34.78 3.6 152 148 40 29.6 82.4 
21 63 M 1.52 68 29.43 110 80 86 26 0.8 90.9 0.73 0.57 9.8 3.63 35.57 3.82 188 134 46 26.8 115 
22 61 M 1.57 67 27.18 100 74 100 24 0.8 91.89 0.91 0.542 9.87 2.85 28.13 3.67 164 140 38 28 98 
23 62 M 1.56 70 28.76 96 70 78 24 0.8 94.79 0.53 0.519 10.2 3.27 33.35 4.65 166 128 45 25.6 95.4 
24 61 M 1.63 72 27.1 94 72 104 20 0.9 87.78 0.25 0.639 10.8 3.09 33.37 3.8 194 136 40 27.2 127 
25 62 M 1.69 68 23.81 106 80 92 18 0.8 92.08 0.36 0.753 9.6 3.3 31.68 4.01 202 120 36 24 142 
26 54 M 1.55 65 27.06 114 86 88 22 0.8 97.05 0.29 0.724 9.79 3.22 31.52 4.89 154 130 42 26 86 
27 45 M 1.7 62 21.45 130 80 76 28 0.9 90.9 0.66 0.661 9.9 3.16 31.28 3.98 168 142 38 28.4 102 
28 50 M 1.6 66 25.78 124 78 100 28 0.8 103.1 0.89 0.87 10.1 3.33 33.63 3.64 165 138 40 27.6 97.4 
MASTER CHART I - CONTROLS 
 
S.No 
AGE 
years SEX 
HT 
m 
WT 
Kg 
BMI 
kg2/m2
 
SBP 
mmHg 
DBP 
mmHg 
FBG 
mg/dl  
UREA 
mg/dl 
CREAT 
mg/dl 
Ccr 
ml/min 
hs-CRP 
mg/L 
FETUIN-A 
g/L 
CAL 
mg/dl 
PHOS 
mg/dl 
CaXP 
mg2/dl2
 
ALB 
g/dl 
TC 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
VLDL 
mg/dl 
LDL 
mg/dl 
29 43 M 1.56 62 25.48 116 70 98 24 0.9 92.81 0.73 0.572 9.85 2.97 29.25 3.7 170 155 43 31 96 
30 55 M 1.65 56 20.57 110 76 94 20 0.8 82.64 0.45 0.648 9.34 3.14 29.33 3.85 182 146 44 29.2 109 
31 52 M 1.58 60 21.63 120 76 84 20 0.8 91.67 0.76 0.86 9.5 3.98 37.81 4.13 152 142 42 28.4 81.6 
32 45 M 1.55 58 19.98 108 72 84 24 0.8 95.66 0.38 0.614 10.4 3.61 37.54 4.24 162 130 40 26 96 
33 52 M 1.67 56 20.08 90 70 76 22 0.7 97.78 0.22 0.638 9.6 4.02 38.59 4.6 172 158 48 31.6 92.4 
34 42 M 1.52 54 23.37 112 84 98 28 0.8 91.88 0.46 0.64 9.87 3.17 31.29 3.8 192 128 38 25.6 128 
35 40 M 1.56 66 27.12 88 70 74 26 0.8 114.6 0.34 0.632 9.54 3.53 33.68 3.56 180 108 38 21.6 120 
36 47 M 1.63 63 23.71 100 74 88 18 0.9 90.42 0.98 0.558 10.5 3.67 38.54 3.84 172 100 42 20 110 
37 41 M 1.68 60 21.26 120 78 88 20 0.8 103.1 0.49 0.62 9.51 3.07 29.2 3.71 200 150 45 30 125 
38 54 M 1.56 68 27.94 104 80 100 20 0.9 90.25 0.65 0.653 9.16 3.22 29.5 3.78 170 122 40 24.4 106 
39 51 M 1.64 62 23.05 110 74 104 22 0.8 95.8 0.97 0.792 9.97 3.29 32.8 4.03 148 134 42 26.8 79.2 
40 50 M 1.52 64 27.7 114 80 102 28 0.8 100 0.73 0.91 9.88 3.6 35.57 3.63 196 126 38 25.2 133 
41 52 M 1.67 76 27.25 90 70 86 26 1 92.89 0.26 0.823 10.3 3.37 34.71 3.68 182 114 40 22.8 119 
42 51 M 1.56 66 27.12 98 72 78 20 0.9 90.65 0.87 0.63 9.9 3.18 31.48 3.98 188 140 42 28 118 
43 52 M 1.62 60 22.86 120 76 78 22 0.8 91.67 0.26 0.96 9.12 3.4 31.01 4.25 176 132 46 26.4 104 
44 43 M 1.6 71 27.73 110 70 86 22 1 95.65 0.92 1.07 10.3 3.07 31.56 4.34 160 106 43 21.2 95.8 
45 47 M 1.72 68 22.99 104 80 98 28 0.9 97.59 0.35 0.88 9.3 3.9 36.27 3.94 165 102 40 20.4 105 
46 42 M 1.53 63 26.91 108 78 100 24 0.8 107.2 0.63 0.935 9.78 3.64 35.6 3.68 178 112 46 22.4 110 
47 40 M 1.66 65 23.59 120 74 84 24 0.9 100.3 0.38 0.81 10.5 3.36 35.28 4.42 160 100 38 20 102 
48 62 M 1.54 67 28.25 110 70 84 20 0.8 90.73 0.82 0.56 9.6 3.7 35.52 4.26 182 128 40 25.6 116 
49 62 M 1.67 68 24.38 126 80 100 28 0.8 92.08 0.57 1.08 9.2 4.13 38 4.7 170 124 36 24.8 109 
50 45 M 1.72 55 18.59 116 74 100 18 0.8 90.71 0.47 0.834 10.3 3.06 31.58 3.6 168 165 48 33 87 
51 48 M 1.6 64 25 100 72 88 22 0.9 90.86 0.95 0.928 9.67 3.51 33.94 3.78 156 120 42 24 90 
52 61 M 1.57 66 26.78 90 70 82 22 0.7 103.5 0.72 0.95 10.3 3.42 35.36 4.36 164 110 40 22 102 
53 62 M 1.64 67 24.91 120 78 78 18 0.8 90.73 0.24 0.61 9.51 3.16 30.05 4.09 158 132 43 26.4 88.6 
54 46 M 1.62 65 24.77 106 74 92 28 0.8 106.1 0.28 0.713 10.3 3.27 33.78 3.76 196 126 45 25.2 126 
                       55 42 M 1.58 56 22.43 96 70 98 26 0.8 95.28 0.41 0.78 9.8 3.76 36.85 3.65 172 146 35 29.2 108 
56 30 F 1.67 60 21.51 120 76 74 26 0.9 101.9 0.76 0.969 9.78 3.18 31.1 4.5 166 158 40 31.6 94.4 
57 33 F 1.52 50 21.64 100 70 100 20 0.8 92.88 0.39 0.94 10.5 3.39 35.6 4.32 182 134 42 26.8 113 
S.No 
AGE 
years SEX 
HT 
m 
WT 
Kg 
BMI 
kg2/m2
 
SBP 
mmHg 
DBP 
mmHg 
FBG 
mg/dl 
UREA 
mg/dl 
CREAT 
mg/dl 
Ccr 
ml/min 
hs-CRP 
mg/L 
FETUIN-A 
g/L 
CAL 
mg/dl 
PHOS 
mg/dl 
CaXP 
mg2/dl2
 
ALB 
g/dl 
TC 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
VLDL 
mg/dl 
LDL 
mg/dl 
58 45 F 1.54 55 23.19 110 74 104 24 0.8 90.71 0.23 0.576 10.2 3.8 38.68 3.64 150 150 36 30 84 
59 35 F 1.52 50 21.64 124 80 74 22 0.8 91.15 0.67 0.971 10.2 3.34 34.07 4.53 168 104 38 20.8 109 
60 33 F 1.56 58 23.83 100 76 88 22 0.9 95.77 0.54 1.12 9.31 3.9 36.31 3.9 194 140 42 28 124 
61 41 F 1.62 63 24.01 100 72 94 20 0.8 108.3 0.59 0.83 10 2.9 29 3.59 202 148 37 29.6 135 
62 43 F 1.6 66 25.78 90 70 86 18 0.9 98.8 0.93 0.676 9.39 3.73 35.02 3.91 168 120 38 24 106 
63 43 F 1.64 65 24.17 106 80 100 22 0.9 97.3 0.81 0.969 10.2 3.17 32.4 4.7 194 162 48 32.4 114 
64 44 F 1.56 64 26.3 110 82 98 28 0.8 106.7 0.63 0.774 9.73 3.33 32.4 3.87 180 140 45 28 107 
65 44 F 1.52 62 26.84 120 78 78 26 0.9 91.85 0.78 0.859 9.34 3.85 35.96 4.25 156 134 40 26.8 89.2 
66 41 F 1.54 56 23.61 108 74 86 20 0.8 96.25 0.25 1.04 10.8 3.43 37.04 4.37 178 154 46 30.8 101 
67 51 F 1.66 64 23.23 116 78 88 24 0.8 98.89 0.59 0.652 9.2 4.01 36.89 4.52 160 142 42 28.4 89.6 
68 63 F 1.58 68 27.24 114 72 102 28 0.8 90.9 0.28 0.633 9.51 2.72 25.87 3.73 180 150 40 30 110 
69 55 F 1.56 62 25.48 100 70 84 20 0.7 104.6 0.37 0.912 9.7 3.89 37.73 3.8 166 122 45 24.4 96.6 
70 62 F 1.58 67 26.84 100 76 74 22 0.8 90.73 0.66 0.864 10.3 3.43 35.43 3.76 152 135 42 27 83 
71 6 F 1.55 47 19.56 104 70 104 18 0.9 97.19 0.71 0.688 10.9 3.19 34.61 4.2 168 140 36 28 104 
72 62 F 1.5 70 31.11 110 74 98 26 0.8 94.79 0.63 0.95 9.28 3.67 34.06 4.52 180 164 44 32.8 103 
73 61 F 1.52 68 29.43 90 70 90 24 0.8 93.26 0.83 0.66 9.3 2.83 26.32 3.9 186 142 40 28.4 118 
74 50 F 1.6 52 20.31 100 78 80 20 0.7 92.86 0.79 0.636 9.67 3.47 33.55 3.71 172 155 38 31 103 
75 52 F 1.57 60 24.34 96 70 72 20 0.8 91.67 0.52 1.23 10.3 3.14 32.28 3.68 150 142 38 28.4 83.6 
76 52 F 1.58 62 24.84 98 72 78 28 0.7 108.3 0.83 0.618 10 3.38 33.8 4.2 184 138 46 27.6 110 
77 51 F 1.55 59 24.56 102 78 90 24 0.8 91.16 0.29 0.671 9.83 3.65 35.88 3.75 180 168 40 33.6 106 
78 51 F 1.58 60 24.03 90 70 100 22 0.8 92.71 0.64 0.98 9.3 3.4 31.62 3.86 166 140 42 28 96 
79 45 F 1.53 64 27.34 120 80 78 22 0.9 93.83 0.31 1.17 9.2 4 36.8 3.93 170 134 38 26.8 105 
80 46 F 1.6 60 23.44 100 74 82 18 0.8 97.92 0.42 0.714 9.31 3.65 33.98 4.15 194 126 42 25.2 127 
 
 
 
 MASTER CHART II- CASES 
S.No AGE  SEX 
HT  
m 
WT 
Kg 
BMI 
kg2/m2
 
SBP 
mmHg 
DBP 
mmHg 
FBG 
mg/dl 
UREA 
mg/dl 
CREAT 
mg/dl 
Ccr 
ml/min 
hsCRP 
mg/L 
FETUIN-A 
g/L 
CAL 
mg/dl 
PHOS 
mg/dl 
Ca X P 
mg2/dl2
 
ALB 
g/dl 
TC 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
VLDL 
mg/dl 
LDL 
mg/dl 
1 55 M 1.7 55 19.03 110 80 130 110 2.03 31.99 3.96 0.55 9.75 4.2 40.95 3.34 196 160 38 32 126 
2 45 M 1.62 45 17.15 130 70 116 90 1.94 30.61 2.99 0.455 9.23 4.38 40.43 3.2 160 230 35 46 79 
3 53 M 1.68 48 17.01 128 84 86 104 1.7 34.12 3.28 0.49 10.5 4 42 3.59 200 170 33 34 133 
4 42 M 1.62 43 16.38 170 100 148 88 1.9 30.8 0.91 0.463 9.51 3.9 37.09 3.67 160 200 40 40 80 
5 39 M 1.58 55 22.03 100 80 134 122 2.32 33.26 4.1 0.47 10.32 3.7 38.18 3.5 184 188 36 37.6 110 
6 63 M 1.64 60 22.31 144 96 140 118 2.13 30.13 3.52 0.442 10.69 4.23 45.22 3.03 176 180 34 36 106 
7 38 M 1.72 67 22.65 120 60 96 90 1.8 52.73 2.04 0.493 10.3 3.94 40.58 2.9 160 168 36 33.6 90.4 
8 42 M 1.56 58 23.83 152 94 80 98 2.1 37.59 2.63 0.52 9.26 4 37.04 4 182 240 43 48 91 
9 58 M 1.68 72 25.51 120 80 102 136 5.1 16.08 7.3 0.31 9 4.5 40.5 2.99 168 230 32 46 90 
10 57 M 1.57 55 22.31 126 82 110 124 3.2 19.81 5.55 0.44 8.9 4.9 43.61 3.72 160 170 40 34 86 
11 42 M 1.6 50 19.53 140 90 128 140 4 17.01 2.51 0.41 8.87 4.72 41.87 3.06 176 210 35 42 99 
12 61 M 1.67 50 17.93 160 80 76 134 3.24 16.93 4.7 0.402 9.8 4.74 46.45 3.39 150 192 38 38.4 73.6 
13 58 M 1.58 52 20.83 180 110 118 130 2.89 20.49 6.91 0.38 9.5 5.57 52.92 3.4 168 184 34 36.8 97.2 
14 50 M 1.66 45 16.33 116 86 72 128 3.22 17.47 3.28 0.393 9.67 4.93 47.67 3.25 174 208 36 41.6 96.4 
15 38 M 1.54 40 16.87 100 70 86 94 2.3 24.64 2.91 0.42 8.73 5.1 44.52 3.13 164 187 32 37.4 94.6 
16 35 M 1.7 86 29.76 124 82 120 126 5.7 22 8.89 0.338 9.3 5.33 49.57 2.57 160 176 42 35.2 82.8 
17 38 M 1.62 53 20.2 140 70 114 130 4.9 15.32 5.58 0.353 9.18 5.42 49.76 2.7 172 152 40 30.4 102 
18 65 M 1.67 72 25.82 110 70 72 114 3 25 2.9 0.412 10.1 4.62 46.66 2.98 176 166 36 33.2 107 
19 73 M 1.73 52 17.37 120 80 106 90 2.81 17.22 10.4 0.37 10.9 4.79 52.21 3.18 184 208 32 41.6 110 
20 75 M 1.78 60 18.94 150 90 132 96 2.3 23.55 7.61 0.313 9.79 4.82 47.19 3.03 172 180 46 36 90 
21 32 M 1.62 55 20.96 150 100 110 104 3.14 26.27 8.7 0.329 8.6 5.2 44.72 3.42 182 192 42 38.4 102 
22 55 M 1.67 65 23.31 114 76 146 92 2.7 28.42 4.53 0.32 8.72 5.59 48.74 3.1 162 152 34 30.4 97.6 
23 47 M 1.73 57 19.05 118 80 86 88 2.5 29.45 3.69 0.241 10.5 4.83 50.72 2.91 174 184 38 36.8 99.2 
24 65 M 1.64 43 15.99 152 84 112 108 3.8 11.79 7.44 0.15 8.9 5.9 52.51 2.59 150 200 38 40 72 
25 65 M 1.53 35 14.95 126 82 120 92 3 12.15 10 0.282 9.33 5.55 51.78 3.1 180 180 28 36 116 
26 64 M 1.58 56 22.43 134 80 104 136 4.6 12.85 9.18 0.31 8.87 6 53.22 2.98 160 208 34 41.6 84.4 
27 75 M 1.48 35 15.98 120 90 72 116 2.79 11.33 10.32 0.303 8.57 6.33 54.25 3.38 168 184 46 36.8 85.2 
28 74 M 1.54 45 18.97 128 82 110 104 3.1 13.31 8.73 0.18 8.53 7 59.71 3.06 190 181 26 36.2 128 
29 35 M 1.65 52 19.1 90 70 82 160 9.1 8.333 7.31 0.252 9.13 5.69 51.95 2.9 164 176 38 35.2 90.8 
  
S.No AGE SEX 
HT 
m 
WT 
Kg 
BMI 
Kg2/m2
 
SBP 
mmHg 
DBP 
mmHg 
FBG  
mg/dl 
UREA  
mg/dl 
CREAT  
mg/dl 
Ccr 
ml/min 
hsCRP 
mg/L 
FETUIN-A 
g/L 
CAL  
mg/dl 
PHOS  
mg/dl 
Ca X P  
mg2/dl2
 
ALB  
g/dl 
TC  
mg/dl 
TGL  
mg/dl 
HDL  
mg/dl 
VLDL  
mg/dl 
LDL  
mg/dl 
30 37 M 1.45 36 17.12 120 80 122 142 8.9 5.787 10.56 0.29 9.21 5.85 53.88 2.63 216 180 32 36 148 
31 53 M 1.62 70 26.67 118 74 90 136 8.3 10.19 9.7 0.233 9.15 6.5 59.48 3.33 160 170 36 34 90 
32 57 M 1.55 58 24.14 124 80 106 128 4.9 13.65 6.91 0.192 8.37 6.93 58 2.52 220 208 28 41.6 150 
33 45 M 1.6 48 18.75 128 86 142 110 4.3 14.73 6.73 0.209 8.96 5.46 48.92 2.13 170 216 40 43.2 86.8 
34 56 M 1.57 62 25.15 170 100 92 134 7.8 9.274 5.82 0.25 9.07 5.88 53.33 2.8 166 192 32 38.4 95.6 
35 57 M 1.55 45 18.73 100 70 80 150 8.9 5.829 10.7 0.357 9.16 5.75 52.67 2.24 206 216 37 43.2 126 
36 48 M 1.72 56 18.93 140 90 86 130 6.4 11.18 8.3 0.172 8.88 6.17 54.79 2.97 176 180 35 36 105 
37 48 M 1.56 45 18.49 124 78 124 156 9.6 5.99 4.86 0.39 8.55 6.43 54.98 3.5 186 144 43 28.8 114 
38 45 M 1.63 57 21.45 110 80 112 80 1.6 47.01 3.2 0.429 9.67 4.2 40.61 3.26 160 184 40 36.8 83.2 
39 45 M 1.55 62 25.81 110 74 74 88 2.2 37.18 0.69 0.44 10.7 3.89 41.62 3.15 190 160 33 32 125 
40 32 M 1.57 50 20.28 160 110 120 90 2 37.5 3.72 0.462 9.53 4.2 40.03 3.33 174 240 37 48 89 
41 54 M 1.71 47 16.07 130 86 88 96 1.8 31.19 1.3 0.49 9.36 4.61 43.15 3.6 208 192 35 38.4 135 
42 38 M 1.63 60 22.58 140 100 70 70 1.4 60.71 0.93 0.856 9.35 4.2 39.27 3.7 174 210 42 42 90 
43 55 M 1.76 68 21.95 150 100 140 60 1.3 61.75 1.54 0.632 11.13 3.1 34.5 3.98 180 220 36 44 100 
44 48 M 1.7 74 25.61 112 80 132 68 1.3 72.74 2.06 0.548 9.4 3.98 37.41 4.1 166 156 38 31.2 96.8 
45 23 M 1.66 55 19.96 120 80 74 72 1.4 63.84 1.2 0.646 9.89 3.67 36.3 3.43 174 198 38 39.6 96.4 
46 48 M 1.59 76 30.06 140 82 104 64 1.3 74.7 3.13 0.59 10.5 3.57 37.49 3.59 162 202 34 40.4 87.6 
47 49 M 1.75 63 20.57 104 80 112 60 1.3 61.25 1.18 0.744 10.13 2.97 30.09 3.33 210 146 45 29.2 136 
48 35 M 1.74 65 21.47 118 70 126 78 1.4 67.71 1.69 0.6 9.2 2.63 24.2 3.08 202 148 42 29.6 130 
49 65 M 1.7 75 25.95 170 110 110 62 1.3 60.1 2.5 0.628 9.8 2.8 27.44 3.64 150 124 45 24.8 80.2 
50 64 M 1.65 77 28.28 120 80 86 58 1.3 62.52 1.04 0.72 9.67 3.03 29.3 4.3 164 136 44 27.2 92.8 
51 45 M 1.72 64 21.63 118 76 74 54 1.3 64.96 2.9 0.695 10.2 2.68 27.34 3.72 178 150 43 30 105 
52 30 M 1.6 58 22.66 110 80 118 60 1.4 63.29 1.16 0.71 10.07 3.1 31.22 3.5 180 148 40 29.6 110 
53 63 M 1.57 52 21.1 124 76 90 84 2.8 19.86 3.66 0.476 9.8 3.27 32.05 3.49 172 190 36 38 98 
54 35 M 1.68 73 25.86 110 70 78 70 1.3 81.89 0.81 0.59 10.6 3.72 39.43 3.6 160 200 33 40 87 
55 55 M 1.51 42 18.42 116 84 130 116 5.1 9.722 3.9 0.469 9.5 5.01 47.6 3.2 206 204 36 40.8 129 
56 58 F 1.54 44 18.55 110 80 128 78 1.3 32.76 2.97 0.542 10.35 4.2 43.47 3.21 178 154 45 30.8 102 
57 49 F 1.56 68 27.94 126 82 80 84 1.9 38.45 3.98 0.48 10.8 4.03 43.52 3.39 160 170 37 34 89 
  
 
S.No AGE SEX 
HT 
m 
WT 
Kg 
BMI 
Kg2/m2
 
SBP 
mmHg 
DBP 
mmHg 
FBG 
mg/dl 
UREA 
mg/dl 
CREAT 
mg/dl 
Ccr 
ml/min 
hsCRP 
mg/L 
FETUIN-A 
g/L 
CAL 
mg/dl 
PHOS 
mg/dl 
CaXP 
mg2/dl2
 
ALB 
g/dl 
TC 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
VLDL 
mg/dl 
LDL 
mg/dl 
58 54 F 1.52 65 28.13 170 100 112 70 1.56 42.3 2.63 0.509 9.7 4.38 42.49 3.7 150 168 42 33.6 74.4 
59 70 F 1.59 75 29.67 162 90 86 68 1.8 34.43 3.7 0.483 10.2 3.96 40.39 3.13 172 208 40 41.6 90.4 
60 33 F 1.55 45 18.73 120 80 74 74 1.6 35.53 4.67 0.497 9.37 4.29 40.2 3.28 184 176 34 35.2 115 
61 58 F 1.62 55 20.96 124 72 72 80 1.4 38.03 5.3 0.462 10.5 4.11 43.16 3.51 160 188 34 37.6 88.4 
62 55 F 1.56 45 18.49 130 80 110 92 2.69 16.79 8.6 0.4 9.13 4.95 45.19 3.58 162 200 35 40 87 
63 55 F 1.5 40 17.78 120 80 80 86 1.7 23.61 5 0.282 8.85 5.31 46.99 2.65 170 194 28 38.8 103 
64 57 F 1.56 60 24.65 114 72 128 98 2.9 20.27 4.93 0.362 9.37 5.6 52.47 2.37 192 168 46 33.6 112 
65 63 F 1.61 46 17.75 156 90 136 130 4.6 9.09 4.89 0.233 9.39 4.79 44.98 2.26 208 192 28 38.4 142 
66 53 F 1.54 47 19.82 160 92 70 148 5.8 8.323 5.6 0.27 9.25 4.93 45.6 2.38 200 184 40 36.8 123 
67 50 F 1.57 52 21.1 150 100 102 126 4.7 11.76 8.26 0.193 8.9 5.68 50.55 3.13 186 178 34 35.6 116 
68 48 F 1.54 45 18.97 120 80 76 150 7.3 6.695 2.15 0.45 8.17 5.33 43.55 3.04 152 190 37 38 77 
69 61 F 1.5 43 19.11 110 80 110 134 5.3 7.567 9.8 0.186 8.76 6.48 56.76 2.6 176 184 48 36.8 91.2 
70 62 F 1.66 56 20.32 114 82 90 104 2.2 23.44 10.9 0.26 9.23 4.39 40.52 2.98 170 212 46 42.4 81.6 
71 57 F 1.7 68 23.53 130 80 138 110 2.5 26.65 9.26 0.325 9.12 4.57 41.68 3.01 162 168 38 33.6 90.4 
72 42 F 1.61 68 26.23 110 80 72 68 1.3 60.52 1.73 0.639 9.68 3.13 30.3 3.21 174 134 40 26.8 107 
73 33 F 1.67 67 24.02 120 84 86 80 1.4 60.45 0.68 0.559 9.13 2.56 23.37 3.39 198 140 45 28 125 
74 62 F 1.55 65 27.06 110 80 112 66 1.6 37.41 2.31 0.45 9.12 4.22 38.49 3.23 160 172 42 34.4 83.6 
75 45 F 1.52 77 33.33 126 84 124 70 1.3 66.43 1.15 0.896 9.71 3.28 31.85 3.7 154 124 45 24.8 84.2 
76 48 F 1.63 75 28.23 110 80 132 68 1.3 62.66 1.21 0.756 10.33 2.63 27.17 3.43 180 114 43 22.8 114 
77 45 F 1.6 78 30.47 106 70 80 82 1.3 67.29 1.9 0.652 10.82 2.69 29.11 3.22 170 160 46 32 92 
78 43 F 1.58 70 28.04 160 100 140 90 1.3 61.66 2.13 0.49 10.5 3 31.5 3.9 176 176 37 35.2 104 
79 30 F 1.57 66 26.78 130 80 72 74 1.4 61.22 1.27 0.876 9.13 3.29 30.04 3.03 180 182 52 36.4 91.6 
80 32 F 1.62 67 25.53 120 70 96 88 1.4 61.02 2.43 0.463 9.6 3.87 37.15 3.18 174 208 38 41.6 94.4 
RESULTS 
 
                A total of 160 subjects were selected as the study group for the 
present study. This includes 80 cases with CKD and 80 healthy controls. 
                Levels of serum Fetuin-A, urea, creatinine, hsCRP, albumin, calcium, 
phosphorus, TC, TGL, HDL-C and FBG were estimated for all the samples of 
the study group. VLDL-C, LDL-C and Creatinine clearance were calculated 
from the formulas.  
                The values obtained in controls and cases are presented in the master 
chart I and II respectively. 
Table 1 shows the baseline characteristics of the controls and cases. 
Table 2 shows the gender-wise distribution of the study group. The distribution 
of males and females in the cases were 68.75% and 31.25% respectively, which 
shows the predominance of CKD in males. 
Table 3 shows the age-wise distribution of the study group. The age group of 
cases ranged from 23-75 years, with the mean age of 50.4±11.89 years and 
median age of 50 years. The age group of controls ranged from 26-68 years, 
with the mean age of 47.85±10.55 years and median age of 46.5 years. 
Table 4 shows the age and gender matched analysis of the study group. There 
is no significant difference between the age and gender of the two groups 
(p=0.628; >0.05 for controls; p=0.812; >0.05 for cases) 
Table 5 shows the serum Fetuin-A levels in the study group. The mean value of 
serum Fetuin-A in cases was 0.4416±0.17 g/L and this was significantly lower 
than that of the control group (0.7527±0.18 g/L; p=0.001) 
Table 6 shows the comparison of serum Fetuin-A levels in various age groups 
in the study subjects. Serum Fetuin-A levels were significantly lower in the 
cases than controls in all the included age groups. 
Table 7 shows the gender-wise comparison of serum Fetuin-A in controls 
(Males: 0.7112±0.16 g/L; Females: 0.8441±0.19 g/L) and cases (Males: 
0.4293±0.16 g/L; Females: 0.4686±0.19 g/L), which is highly significant 
(p=0.001). 
Table 8 shows the gender-wise comparison of serum Fetuin-A levels within the 
cases (Males: 0.4293±0.16 g/L; Females: 0.4686±0.19 g/L). There is no 
significant difference of Fetuin-A levels between the genders in the cases 
(p=0.341; >0.05).  
Table 9 shows the comparison of FBG, blood urea and creatinine and CCr in the 
study group. There is no significant difference in FBG between the two groups 
(p=0.122; > 0.05). Blood urea was found to be significantly higher and serum 
creatinine and CCr were significantly lower in the cases than controls 
(p=0.001). 
Table 10 shows the comparison of serum hsCRP and albumin levels in the 
study group. hsCRP levels were significantly higher and albumin levels were 
significantly lower in the cases than controls (p=0.001). 
Table 11 shows the comparison of serum calcium, phosphorus and calcium-
phosphorus product in the study group. Serum calcium levels were found to be 
significantly lower and the serum phosphorus and Ca X P were significantly 
higher in the cases than controls (p=0.001).  
Table 12 shows the comparison of lipid parameters in the study group. We 
observed significantly higher serum TGL and VLDL-C levels and significantly 
lower HDL-C levels in the cases than controls (p< 0.0001). There is no 
significant difference in the TC and LDL-C levels between the two groups 
(p=0.192; >0.05). 
Table 13 shows the comparison of serum Fetuin-A levels in the study group in 
relation to CCr. As the renal function declined, we observed a progressive 
reduction in the Fetuin-A levels in cases when compared to controls. 
Table 14 shows the comparison of serum hsCRP levels in the study group in 
relation to CCr. We observed a progressive increase in the hsCRP values in 
cases as the renal function declined when compared to controls. 
Table 15 shows the comparison of blood urea levels in the study group in 
relation to CCr. There is a progressive increase in the urea values in cases with 
lessening renal function as compared to controls. 
Table 16 shows the comparison of serum creatinine levels in the study group in 
relation to CCr. We observed a progressive reduction of creatinine values as the 
renal function decreased in cases. Serum creatinine levels were within the 
normal reference range in the controls. 
Table 17 shows comparison of serum calcium levels in the study group in 
relation to CCr. There is a serial reduction in the calcium levels with declining 
renal function in cases. Serum calcium levels were within the normal reference 
range in the controls. 
Table 18 shows the comparison of serum phosphorus levels in the study group 
in relation to CCr. We observed a progressive increase in the phosphorus levels 
in the cases as the renal function declined. Serum phosphorus levels were 
within the normal reference range in the controls. 
Table 19 shows the comparison of Ca X P levels in the study group in relation 
to CCr. There is a progressive increase in the Ca X P values in cases with 
lessening renal function. Ca X P was within the normal reference range in the 
controls. 
Table 20 shows the comparison of serum albumin levels in the study group in 
relation to CCr. We observed a progressive reduction of albumin levels as the 
renal function decreased in the cases. Serum albumin levels were within the 
normal reference range in the controls. 
Table 21 shows the comparison of lipid parameters in the study group in 
relation to CCr. Serum TC and LDL-C levels were found to be within the 
normal reference range in the cases irrespective of CCr. We observed a serial 
increase in the TGL and VLDL-C levels and a serial decrease in the HDL-C 
levels with lessening renal function. 
Table 22 shows the Pearson’s coefficient of correlation between serum Fetuin-
A and the other studied biochemical parameters in the cases. There is a highly 
significant negative correlation of Fetuin-A with serum urea, creatinine, 
hsCRP, phosphorus, Ca X P, TGL and VLDL-C (p < 0.01). We also observed a 
highly significant positive correlation of Fetuin-A with CCr, albumin, calcium 
and    HDL-C.  
Figure 13: Bar diagram showing the serum Fetuin-A levels in the study group. 
Figure14: Bar diagram showing the comparison of serum hsCRP and albumin 
levels in the study group. 
Figure15: Bar diagram showing the comparison of serum calcium, phosphorus 
and calcium-phosphorus product in the study group. 
Figure 16: Bar diagram showing the comparison of serum Fetuin-A levels in 
the study group in relation to creatinine clearance. 
Figure 17: Bar diagram showing the comparison of serum hsCRP levels in the 
study group in relation to creatinine clearance. 
Figure 18: Bar diagram showing the comparison of serum calcium-phosphorus 
product in the study group in relation to creatinine clearance. 
Figure 19: Scatter diagram of serum Fetuin-A vs hsCRP in controls 
Figure 20: Scatter diagram of serum Fetuin-A vs hsCRP in cases 
Figure 21: Scatter diagram of serum Fetuin-A vs albumin in controls 
Figure 22: Scatter diagram of serum Fetuin-A vs albumin in cases 
Figure 23: Scatter diagram of serum Fetuin-A vs phosphorus in controls 
Figure 24: Scatter diagram of serum Fetuin-A vs phosphorus in cases 
Figure 25: Scatter diagram of serum Fetuin-A vs calcium-phosphorus product 
in controls 
Figure 26: Scatter diagram of serum Fetuin-A vs calcium-phosphorus product 
in cases 
Figure 27: Scatter diagram of serum Fetuin-A vs creatinine clearance in 
controls 
Figure 28: Scatter diagram of serum Fetuin-A vs creatinine clearance in cases 
Figure 29: Scatter diagram of serum Fetuin-A vs TGL in controls 
Figure 30: Scatter diagram of serum Fetuin-A vs TGL in cases 
Figure 31: Scatter diagram of serum Fetuin-A vs HDL-C in controls 
Figure 32: Scatter diagram of serum Fetuin-A vs HDL-C in cases 
 
 
 
 
  
STATISTICAL ANALYSIS 
 Student’s t-test and Chi-square test were employed for the statistical 
analysis of data.  
 The data were expressed in terms of mean and standard deviation.  
 ‘P’ value less than 0.05 was taken as the significant value.  
 Correlation between the measured parameters was assessed using 
Pearson’s correlation coefficient. 
 
 
 
 
TABLE 1 
 
                          DESCRIPTIVE STATISTICS OF THE STUDY GROUP 
 
 
 
 
 
 
S.NO 
PARAMETERS 
CONTROLS (n=80) CASES (n=80) 
MIN. MAX. MEAN S.D MIN. MAX. MEAN S.D 
1 AGE (years) 26 68 47.85 10.552 23 75 50.40 11.895 
2 HEIGHT (m) 1.50 1.72 1.603 0.0591 1.45 1.78 1.6146 .0723 
3 WEIGHT (kg) 47 76 63.19 5.934 35 86 57.33 11.775 
4 BMI (kg/m2) 18.591 31.111 24.561 2.700 14.951 33.327 21.942 4.163 
5 SBP (mmHg) 88 130 106.70 10.636 90 180 128.32 19.721 
6 DBP (mmHg) 70 86 74.97 4.173 60 110 83.03 10.208 
7 S.FETUIN-A (g/L) 0.51 1.23 0.752 0.176 0.15 0.90 0.4416 0.170 
8 FBG (mg/dl) 72 104 91.05 9.657 70 148 103.67 23.098 
9 B.UREA (mg/dl) 18 28 22.92 3.244 54 160 99.95 27.731 
10 S.CREAT (mg/dl) 0.70 1.10 0.841 0.082 1.30 9.60 3.068 2.153 
11 Ccr (ml/min) 79.166 134.58 96.476 8.409 5.786 81.891 32.994 21.241 
12 S.hsCRP (mg/L) 0.21 0.98 0.568 0.232 0.68 10.90 4.618 3.037 
13 S.CALCIUM (mg/dl) 9.12 10.90 9.905 0.497 8.17 11.13 9.542 0.675 
14 S.PHOS (mg/dl) 2.67 4.30 3.410 0.367 2.56 7.00 4.539 1.105 
15 Ca X P (mg2/dl2) 25.867 39.900 33.711 3.285 23.372 59.710 42.844 8.718 
16 S.ALBUMIN (g/dl) 3.56 4.89 4.005 0.332 2.13 4.30 3.208 0.432 
17 S.TC (mg/dl) 160 208 173.575 14.501 150 220 175.375 16.343 
18 S.TGL (mg/dl) 100 168 133.96 16.363 114 240 182.50 26.576 
19 S.HDL-C (mg/dl) 35 50 41.72 3.368 26 52 38.03 5.202 
20 S.VLDL-C (mg/dl) 20.00 33.60 26.792 3.272 22.80 48.00 36.500 5.315 
21 S.LDL-C (mg/dl) 84.00 142.60 105.057 14.74 61.00 150.40 101.065 18.089 
TABLE 2 
 
GENDERWISE DISTRIBUTION OF THE STUDY GROUP 
 
 
 
 
 
 
 
 
 
TABLE 3 
 
AGEWISE DISTRIBUTION OF THE STUDY GROUP 
 
 
 
 
 
GROUPS GENDER 
MALE (%) FEMALE (%) 
 
CONTROLS (n=80) 
 
55 (68.75%) 
 
25 (31.25%) 
 
CASES (n=80) 
 
55 (68.75%) 
 
25 (31.25%) 
GROUPS AGE (YEARS) MEDIAN 
AGE 
(YEARS) 
RANGE  
(YEARS) 
 
MEAN SD 
 
CONTROLS (n=80) 
47.85 10.552 
 
46.5 
 
26-68 
 
CASES (n=80) 
50.40 11.895 
 
50 
 
23-75 
  
TABLE 4 
 
AGE AND GENDER MATCHED ANALYSIS OF THE STUDY GROUP 
 
 
 
 
 
 
 
S.No Age 
Gender 
Controls Cases 
Male  
(n=55) 
Female 
(n=25) 
Statistical 
Inference 
Male  
(n=55) 
Female 
(n=25) 
Statistical 
Inference 
1 
Below 
30yrs 
2 (3.6%) 
 
1 (4%) 
 
χ 2 =2.592 
P=0.628      
Not 
Significant 
 
2 
(3.6%) 
1 (4%) 
χ 2 = 1.582 
P=0.812         
Not 
significant 
 
2 
31 to 
40yrs 
14 
(25.5%) 
3 
(12%) 
 
12 
(12.8%) 
3 
(12%) 
3 
41 to 
50yrs 
15 
(27.3%) 
10 
(40%) 
15 
(27.3%) 
8 
(32%) 
4 
51 to 
60 
years 
11 
(20%) 
 
6 
(24%) 
 
13 
(23.6%) 
8 
(32%) 
5 
>60 
years 
13 
(23.6%) 
5 
(20%) 
13 
(23.6%) 
5 
(20%) 
TABLE 5 
COMPARISON OF SERUM FETUIN-A IN THE STUDY GROUP 
    
 
 
Figure 13 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
S.NO GROUPS 
S.FETUIN-A (g/L) STATISTICAL 
INFERENCE MEAN SD 
1 CONTROLS (n=80) 0.7527 0.17686 T=11.344 
P<0.001 
Significant 
2 CASES (n=80) 0.4416 0.17002 
0.7527 
0.4416 
0
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                                                             TABLE 6 
        AGE MATCHED ANALYSIS OF SERUM FETUIN-A LEVELS IN THE  
                                                        STUDY GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
           
          
 
 
 
 
 
                                                       
 
 
AGE 
S.FETUIN-A (g/L) STATISTICAL 
INFERENCE GROUPS MEAN SD 
< 30 yrs 
CONTROLS 
(n=3) 
0.7390 0.22111 
T = 8.135 
P=0.007 
Significant CASES (n=3) 0.6440 0.11871 
31-40 yrs 
CONTROLS 
(n=17) 
0.7532 0.19389 
T = 4.639 
P<0.001 
Significant CASES (n=15) 0.4648 0.15180 
41-50 yrs 
CONTROLS 
(n=25) 
0.7932 0.16947 
T = 5.902 
P<0.001 
Significant CASES (n=23) 0.4893 0.18718 
51-60 yrs 
CONTROLS 
(n=17) 
0.7598 0.18164 
T = 7.484 
P<0.001 
Significant CASES (n=21) 0.3936 0.11879 
>60 yrs 
CONTROLS 
(n=18) 
0.6916 0.16181 
T = 6.200 
P<0.001 
Significant CASES (n=18) 0.3667 0.15254 
TABLE 7 
GENDER MATCHED COMPARISON OF SERUM FETUIN-A LEVELS IN 
THE STUDY GROUP 
                
                                                                 
TABLE 8 
GENDERWISE DIFFERENCE OF SERUM FETUIN-A LEVEL IN CASES 
 
.NO 
             
GENDER 
S.FETUIN-A 
(g/L) STATISTICAL 
INFERENCE 
 MEAN SD 
1 MALE (n=55) 0.4293 0.15985 T = -0.959 
P=0.341 
Not Significant 
2 FEMALE (n=25) 0.4686 0.19119 
 
 
 
 
 
GENDER GROUPS S.FETUIN-A 
(g/L) 
STATISTICAL 
INFERENCE 
MEAN SD 
MALE CONTROLS (n=55) 0.7112 0.15636 T=9.350 
P<0.001 
Significant 
CASES  (n=55) 0.4293 0.15985 
FEMALE CONTROLS (n=25) 0.8441 0.18790 T=7.004 
P<0.001 
Significant 
CASES  (n=25) 0.4686 0.19119 
  
TABLE 9 
 
COMPARISON OF FBG, BLOOD UREA, SERUM CREATININE AND  
CREATININE CLEARANCE (Ccr) IN THE STUDY GROUP 
 
PARAMETERS 
GROUPS MEAN SD 
STATISTICAL 
INFERENCE 
FBG (mg/dl) CONTROLS (n=80) 91.05 9.65 T=12.307 
P=0.102 
Not Significant 
CASES (n=80) 103.68 23.09 
B.UREA (mg/dl) CONTROLS (n=80) 22.93 3.24 T=-24.675 
P<0.001 
Significant 
CASES (n=80) 99.95 27.73 
S.CREATININE 
(mg/dl) 
CONTROLS (n=80) 0.84 0.08 T=-9.243 
P<0.001 
Significant 
CASES (n=80) 3.068 2.15 
Ccr (ml/min) CONTROLS (n=80) 96.47 8.40 T=24.854 
P<0.001 
Significant 
CASES (n=80) 32.99 21.24 
 
 
 
 
    
TABLE 10 
COMPARISON OF SERUM hsCRP AND ALBUMIN IN THE STUDY GROUP 
 
PARAMETERS 
GROUPS MEAN SD 
STATISTICAL 
INFERENCE 
S.hsCRP (mg/L) 
 
CONTROLS (n=80) 0.5681 0.2327 T=-11.893 
P<0.001 
Significant 
CASES (n=80) 4.6189 3.0376 
S.ALBUMIN 
(g/dl) 
CONTROLS (n=80) 4.0055 0.3326 T=13.060 
P<0.001 
Significant 
CASES (n=80) 3.2087 0.4325 
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TABLE 11 
COMPARISON OF SERUM CALCIUM, PHOSPHORUS AND 
CALCIUM-PHOSPHORUS PRODUCT IN THE STUDY GROUP 
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CONTROLS
CASES
PARAMETERS 
GROUPS MEAN S.D 
STATISTICAL 
INFERENCE 
S.CALCIUM 
(mg/dl) 
CONTROLS (n=80) 9.9058 0.4971 T=3.273 
P<0.001 
Significant 
CASES (n=80) 9.5426 0.6754 
S.PHOSPHORU
S (mg/dl) 
CONTROLS (n=80) 3.4105 0.3676 T=-8.667 
P<0.001 
Significant 
CASES (n=80) 4.5394 1.1054 
Ca X P  
(mg
2
/dl
2
) 
CONTROLS (n=80) 33.7118 3.2850 T=-8.768 
P<0.001 
Significant 
CASES (n=80) 42.8447 8.7187 
TABLE 12 
 
COMPARISON OF LIPID PARAMETERS IN THE STUDY GROUP 
 
 
 
 
 
 
PARAMETERS 
     GROUPS MEAN S.D 
STATISTICAL 
INFERENCE 
S.TC        
(mg/dl) 
CONTROLS (n=80) 173.57 14.74 T=1.309 
P=0.462 
Not Significant 
CASES (n=80) 175.37 18.08 
S.TGL      
(mg/dl) 
CONTROLS (n=80) 133.96 16.36 T=-13.910 
P<0.001 
Significant 
CASES (n=80) 182.50 26.57 
S.HDL-C 
(mg/dl) 
CONTROLS (n=80) 41.73 3.36 T=5.340 
P<0.001 
Significant 
CASES (n=80) 38.03 5.202 
S.VLDL-C 
(mg/dl) 
CONTROLS (n=80) 26.79 3.27 T=-13.910 
P<0.001 
Significant 
CASES (n=80) 36.50 5.31 
S.LDL-C  
(mg/dl) 
CONTROLS (n=80) 105.05 14.74 T=3.528 
P<0.128 
Not Significant 
CASES (n=80) 101.06 18.08 
TABLE 13 
     COMPARISON OF SERUM FETUIN-A IN THE STUDY GROUP IN 
RELATION TO CREATININE CLEARANCE 
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TABLE 14 
       COMPARISON OF SERUM hsCRP IN THE STUDY GROUP IN    
RELATION TO CREATININE CLEARANCE 
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S.hsCRP (mg/L) 
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Ccr (ml/min) 
1.632 0.7014 60 to 90 (n=20) 
30 to 59 (n=20) 3.0795 1.1962 
15 to 29 (n=20) 6.206 2.6283 
< 15 (n=20) 7.558 2.4301 
TOTAL CASES (n=80) 
 
4.6189 
 
3.0376 
 
CONTROLS (n=80) 
 
0.5681 
 
0.2327 
TABLE 15: COMPARISON OF BLOOD UREA IN THE STUDY GROUP IN 
RELATION TO CREATININE CLEARANCE 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 16:  COMPARISON OF SERUM CREATININE IN THE STUDY 
GROUP IN RELATION TO CREATININE CLEARANCE 
 
 
 
  
 
 
 
 
 
 
 
          GROUPS 
B.UREA (mg/dl) 
MEAN SD 
Ccr  (ml/min) 
69.8 9.903 60 to 90 (n=20) 
30 to 59 (n=20) 89.1 15.553 
15 to 29 (n=20) 110.6 18.785 
< 15 (n=20) 130.3 18.299 
TOTALCASES (n=80) 
 
99.95 
 
27.731 
CONTROLS (n=80) 
 
22.93 
 
3.244 
GROUPS 
S.CREAT (mg/dl) 
MEAN SD 
Ccr (ml/min) 
1.335 0.0489 60 to 90 (n=20) 
30 to 59 (n=20) 1.859 0.3061 
15 to 29 (n=20) 3.1645 1.0203 
< 15 (n=20) 5.9145 2.2151 
TOTAL CASES (n=80) 
 
3.0683 
 
2.15350 
 
CONTROLS (n=80) 
 
0.8412 
 
0.08221 
   
                                            
 
TABLE 17 
 
COMPARISON OF SERUM CALCIUM IN THE STUDY GROUP 
IN RELATION TO CREATININE CLEARANCE 
 
 
            
       
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
GROUPS 
S.CALCIUM (mg/dl) 
MEAN SD 
Ccr (ml/min) 
9.942 0.5784 60 to 90 (n=20) 
30 to 59 (n=20) 9.868 0.5682 
15 to 29 (n=20) 9.328 0.5608 
< 15 (n=20) 8.9325 0.3555 
   
TOTAL CASES (n=80) 9.5426 0.6754 
 
CONTROLS (n=80) 
 
9.9058 
 
0.49711 
   
  
TABLE 18 
 
COMPARISON OF SERUM PHOSPHORUS IN THE STUDY 
GROUP IN RELATION TO CREATININE CLEARANCE 
 
 
GROUPS 
S.PHOSPHORUS 
(mg/dl) 
MEAN SD 
Ccr (ml/min) 
3.195 0.4918 60 to 90 (n=20) 
30 to 59 (n=20) 4.1635 0.2607 
15 to 29 (n=20) 4.916 0.5384 
< 15 (n=20) 5.883 0.6171 
   TOTAL CASES (n=80) 4.5394 1.1054 
 
CONTROLS (n=80) 
3.4105 0.3676 
 
 
 
 
 
 
 
 
TABLE 19 
COMPARISON OF SERUM CALCIUM-PHOSPHORUS PRODUCT IN 
THE STUDY GROUP IN RELATION TO CREATININE CLEARANCE 
GROUPS 
Ca X P (mg
2
/dl
2
) 
MEAN SD 
Ccr (ml/min) 
31.723 4.8416 60 to 90 (n=20) 
30 to 59 (n=20) 41.466 3.0865 
15 to 29 (n=20) 45.765 4.9648 
< 15 (n=20) 52.425 4.5444 
TOTAL CASES (n=80) 
 
42.844 
 
8.718 
 
CONTROLS (n=80) 
 
33.711 
 
3.285 
 
Figure 18 
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 TABLE 20 
 
COMPARISON OF SERUM ALBUMIN IN THE STUDY GROUP IN 
RELATION TO CREATININE CLEARANCE 
 
 
GROUPS 
S.ALBUMIN (g/dl) 
MEAN SD 
Ccr (ml/min) 
3.5515 0.3416 60 to 90 (n=20) 
30 to 59 (n=20) 3.3465 0.2785 
15 to 29 (n=20) 3.1 0.3483 
< 15 (n=20) 2.837 0.4011 
   
TOTAL CASES (n=80) 3.2087 0.4325 
 
CONTROLS (n=80) 
 
4.0055 
 
0.3326 
    
 
 
 
 
 
 
 
 TABLE 21 
 
  COMPARISON OF LIPID PARAMETERS IN CASES IN RELATION TO  
CREATININE CLEARANCE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PARAMETERS 
Ccr (ml/min) 
60-90 
(n=20) 
30-50 
(n=20) 
15-29 
(n=20) 
<15 
(n=20) 
S.TC (mg/dl)     
MEAN 179.60 176.40 173.30 187.60 
SD 15.756 15.608 11.131 19.699 
S.TGL (mg/dl)     
MEAN 164.30 187.20 188.35 190.15 
SD 33.594 22.816 17.160 22.816 
S.HDL-C (mg/dl)     
MEAN 41.30 37.60 37.40 35.80 
SD 4.646 3.560 5.103 5.926 
S.VLDL-C (mg/dl)     
MEAN 32.86 37.44 37.67 38.03 
SD 6.7187 4.5632 4.5765 3.4319 
S.LDL-C (mg/dl)     
MEAN 105.44 101.36 97.87 114.13 
SD 16.7605 19.9041 13.3826 21.9760 
 TABLE 22 
 
PEARSON’S CORRELATION COEFFICIENT BETWEEN S.FETUIN-A AND  
OTHER BIOCHEMICAL PARAMETERS IN CASES (n=80) 
 
  
    ** Correlation is significant at P<0.01 level                                 
 
 
PARAMETERS CORRELATION VALUE 
STATISTICAL 
INFERENCE 
B.UREA (mg/dl) -.691(**) P < 0.01 Significant 
S.CREATININE 
(mg/dl) 
-.595(**) P < 0.01 Significant 
Ccr (ml/min) .855(**) P < 0.01 Significant 
S.hsCRP (mg/L) -.756(**) P < 0.01 Significant 
S.CALCIUM (mg/dl) .464(**) P < 0.01 Significant 
S.PHOSPHORUS 
(mg/dl) 
-.819(**) P < 0.01 Significant 
Ca X P (mg
2
/dl
2
) -.818(**) P < 0.01 Significant 
S.ALBUMIN (g/dl) .616(**) P < 0.01 Significant 
S.TC (mg/dl) -.078 P > 0.05 Not Significant 
S.TGL (mg/dl) -.366(**) P < 0.01 Significant 
S.HDL-C (mg/dl) .443(**) P < 0.01 Significant 
S.VLDL-C (mg/dl) -.366(**) P < 0.01 Significant 
S.LDL-C (mg/dl) -.086 P > 0.05 Not Significant 
Figure 19: SCATTER DIAGRAM OF SERUM FETUIN-A VS hsCRP IN 
CONTROLS 
 
 
 
Figure 20: SCATTER DIAGRAM OF SERUM FETUIN-A VS hsCRP IN 
CASES 
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Figure 21: SCATTER DIAGRAM OF SERUM FETUIN-A VS ALBUMIN 
IN CONTROLS 
 
                   
 
Figure 22: SCATTER DIAGRAM OF SERUM FETUIN-A VS ALBUMIN 
IN CASES 
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Figure 23: SCATTER DIAGRAM OF SERUM FETUIN-A VS 
PHOSPHORUS IN CONTROLS 
 
                       
 
Figure 24: SCATTER DIAGRAM OF SERUM FETUIN-A VS 
PHOSPHORUS IN CASES 
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Figure 25: SCATTER DIAGRAM OF SERUM FETUIN-A VS 
CALCIUM-PHOSPHORUS PRODUCT IN CONTROLS 
 
                       
 
Figure 26: SCATTER DIAGRAM OF SERUM FETUIN-A VS 
CALCIUM-PHOSPHORUS PRODUCT IN CASES 
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Figure 27: SCATTER DIAGRAM OF SERUM FETUIN-A VS 
CREATININE CLEARANCE IN CONTROLS 
 
                       
 
Figure 28: SCATTER DIAGRAM OF SERUM FETUIN-A VS 
CREATININE CLEARANCE IN CASES 
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Figure 29: SCATTER DIAGRAM OF SERUM FETUIN-A VS TGL IN 
CONTROLS 
 
                    
 
Figure 30: SCATTER DIAGRAM OF SERUM FETUIN-A VS TGL IN 
CASES 
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Figure 31: SCATTER DIAGRAM OF SERUM FETUIN-A VS HDL IN 
CONTROLS 
 
                      
 
Figure 32: SCATTER DIAGRAM OF SERUM FETUIN-A VS HDL IN 
CASES 
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DISCUSSION 
                           In the present study, serum Fetuin-A concentrations were 
found to be significantly decreased in patients with CKD [Mean value: 
0.4416±0.17 g/L] when compared to the control group [Mean value: 
0.7527±0.18 g/L; p=0.001].      
                           When patients in different stages of CKD were compared, 
Fetuin-A levels were found to be progressively decreased from stage 2 
(CCr=60-90 ml/min) to stage 5 (CCr<15 ml/min), in comparison with the control 
group.  This observation shows that reduction in serum Fetuin-A levels develop 
relatively in the early stages of CKD. This finding is supported further by the 
highly significant negative correlation observed between serum Fetuin-A and 
creatinine in CKD cases (r=-0.595, p<0.01).  
                           These findings are in accordance with the study of Cagler et 
al., which reported a decrease in serum Fetuin-A levels in all stages of CKD, 
except stage 1
75
. Lower levels of serum Fetuin-A were also reported in 
hemodialysis patients in the previous studies
76,77
. 
                          The mean level of serum Fetuin-A in CKD cases in the present 
study is 0.4416±0.17 g/L. This finding is almost consistent with that of Cottone 
et al., where the mean Fetuin-A concentration was 0.53±0.17 g/L in patients 
with CKD
78
. We also observed that serum Fetuin-A levels were significantly 
lower in all age groups and in both genders when compared to controls, which 
indicates that age and gender does not have an impact on serum Fetuin-A 
levels. 
                          CKD is a state of chronic persistent low-grade inflammation in 
which there is a chronic systemic elevation of pro-inflammatory markers. The 
prototypic marker of inflammation in the clinical setting is hsCRP, a positive 
acute phase reactant and higher level of this inflammatory biomarker is 
associated with cardiovascular mortality in patients with renal 
insufficiency
79,80
.  
                          In the present study, we observed significantly higher levels of 
hsCRP in CKD cases when compared to controls [Mean level: Cases-
4.618±3.03 mg/L; Controls- 0.567±0.23 mg/L; p=0.001]. As the renal function 
declined, we observed a progressive increase in the hsCRP levels. Further a 
strong inverse correlation was found between Fetuin-A and hsCRP levels (r=-
0.756; p<0.01) which shows that Fetuin-A is a negative acute phase reactant.  
                          Serum albumin is regarded as one of the negative acute phase 
reactant and a low serum albumin level in CKD is a well established predictor 
of mortality
81
. In the present study, serum albumin was found to be 
significantly reduced in CKD cases [Mean level: Cases-3.2±0.43g/dl; Controls- 
4.005±0.33g/dl; p=0.001]. We also observed a progressive decrease in the 
serum albumin levels with declining renal function. The results also revealed a 
strong positive correlation of serum Fetuin-A with albumin levels (r=0.616; 
p<0.01).  
                          These results of the present study are in accordance with the 
previous studies
82,91
, suggesting a global pro-atherogenic inflammatory 
activation even in early stages of CKD leading onto down regulation of serum 
Fetuin-A.   
                          Hyperphosphatemia due to phosphorus retention is associated 
with increased mortality in individuals with moderate to severe CKD
83
. In the 
present study, the serum phosphorus levels were found to be significantly 
elevated in CKD cases [Mean level: Cases- 4.54±1.1mg/dl; Controls- 
3.41±0.37mg/dl; p=0.001]. The results also showed a progressive increase in 
the phosphorus levels as the renal function declined. We also found a strong 
significant negative correlation of serum Fetuin-A with phosphorus levels (r=-
0.819; p<0.01). Serum calcium levels were found to be significantly reduced in 
CKD cases [Mean level: Cases- 9.54±0.67mg/dl; Controls- 9.9±0.41mg/dl; 
p=0.001]. Fetuin-A showed a significant positive correlation with serum 
calcium (r=0.464; p<0.01). 
                          Similar to serum phosphorus, our results also showed a highly 
significant increase of calcium-phosphorus product (Ca X P) in CKD cases 
[Mean level: Cases- 42.84±8.7mg
2
/dl
2
; Controls- 33.71±3.28mg
2
/dl
2
; p=0.001] 
and a progressive increase in Ca X P as the renal function declined. We also 
found a strong significant inverse correlation of serum Fetuin-A with Ca X P 
(r=-0.818; p<0.01). Similar findings were observed in the previous studies
84,85
.  
                          The possible mechanism for this observation could be that, 
serum Fetuin-A is a circulating inhibitor of vascular and soft tissue 
calcification and it avidly binds to both calcium and phosphate in the serum 
forming small calciprotein particles which are removed by macrophages. 
Fetuin-A thus acts as a “buffer” of serum calcium-phosphate to prevent 
extraskeletal calcification. In CKD, increased serum levels of calcium-
phosphate may consume the circulating   Fetuin-A and thereby decrease its 
levels.   
                          Dyslipidemia, an atherosclerotic risk factor, contributes to the 
initiation and progression of CKD partly by stimulating and amplifying the 
effect of inflammatory mechanisms
87
. In the present study, we observed a 
significantly higher serum TGL and VLDL-C levels in cases than controls 
(p=0.001). Serum TC and LDL-C were found to be within the normal reference 
range in our study group. Further we observed a significant negative correlation 
of serum Fetuin-A with TGL and VLDL-C (r=-0.366; p<0.01) and a positive 
correlation of serum Fetuin-A with HDL-C (r=0.443; p<0.01). 
                           These findings are in accordance with the study of Zeiden et 
al., who in addition observed elevated levels of TC and LDL-C
86
. The reason 
for this conflicting result could be explained by the fact that, in CKD patients 
with concomitant inflammation and malnutrition, TC and LDL-C levels may be 
low. 
                          Previous studies have demonstrated that reduced serum Fetuin-
A levels could be considered as a predictor of both cardiovascular and non-
cardio vascular mortality
88,92
. Hermans et al., found that an increment of 0.1g/L 
concentration of serum Fetuin-A resulted in a 13% reduction in the all-cause 
mortality
6
. Cagler et al., demonstrated that short term treatment with 
Sevelamer, a non-calcium-based phosphate binder in patients with CKD, 
increased serum Fetuin-A concentration which in turn improved the endothelial 
dysfunction in these patients
93
.  
                                Taken together, the results of the present study suggest that 
since Fetuin-A is a circulating inhibitor of calcium-phosphate precipitation, the 
available Fetuin-A is depleted in dealing with the elevated Ca X P commonly 
found in CKD. Further, in the chronic inflammatory state of CKD, the 
synthesis of Fetuin-A, a negative acute phase reactant is down regulated. 
Hence, prolonged exposure to a pro-calcific and a pro-inflammatory 
environment in CKD eventually lead onto the reduced production and 
increased consumption of serum Fetuin-A. These findings highlight the close 
relationship between inflammation and vascular calcification in CKD.  
                                               
 
 
 
 CONCLUSION 
 The present study demonstrated that serum Fetuin-A concentrations are 
significantly reduced in patients with CKD. This decrease in Fetuin-A 
levels is progressive, beginning from the early stages of CKD.  
 The chronic inflammatory state and the altered mineral metabolism 
prevailing in CKD could be responsible for the lowered levels of serum 
Fetuin-A. 
 Thus, vascular calcification and the resultant cardiovascular disease are 
likely to develop early during the progression of CKD.  
 Since no approved measures are available currently to increase the 
serum Fetuin-A levels, early and aggressive treatment of inflammation, 
hyperphosphatemia and dyslipidemia may favour an increase in the 
serum Fetuin-A concentrations and subsequently slow down the 
accelerated course of cardiovascular disease in CKD.    
                                            
 
 
 
 
  
LIMITATIONS OF THE STUDY 
 
     Application of imaging techniques would have helped us to 
evaluate the extent of vascular calcification in CKD. 
     Studies on Fetuin-A gene polymorphism would have helped us to 
evaluate the impact of variations in the gene encoding Fetuin-A on the 
protein product and outcome. 
 
 
 
 
 
 
 
 
 
  
SCOPE FOR FURTHER STUDY 
 
                        With cardiovascular disease being increasingly viewed to be 
mediated partly by inflammatory processes, Fetuin-A which is a negative acute 
phase reactant, might prove to be a valuable therapeutic target to prevent 
vascular calcification and mortality in CKD. Strategies aimed at enhancing the 
serum levels of Fetuin-A may have therapeutic benefits.  
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A STUDY OF SERUM FETUIN-A LEVEL IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE 
PROFORMA 
Name of the patient   :                                                                   OP/IP No.: 
Age/sex                     : 
Occupation                : 
Address                     : 
Complaints               :  Oliguria / nocturia/ dysuria/ pedal edema/ anasarca/ 
fever/   
                                     weight loss 
Past history               :  Hypertension/ Diabetes/ Tuberculosis/ Cerebrovascular  
                                     disease/ Liver disease/ Rheumatoid arthritis 
Personal history        :  Diet/ Tobacco/ alcohol/ cigarette use 
Family history          :  Hypertension/ Diabetes/ Renal disease 
Treatment history     :  Drugs (lipid lowering drugs, calcium/phosphate 
binders)/    
                                     Renal replacement therapy (Hemodialysis/ Peritoneal  
                                     dialysis/ renal transplantation)  
General examination:   
        Height:             cms;              Weight:             kg;                    BMI:        
kg/m
2 
        Pulse Rate:              /min;      Blood Pressure:                   mmHg        
 
Systemic examination: 
Cardiovascular system: 
Respiratory system: 
Abdomen: 
Central nervous system: 
PROVISIONAL DIAGNOSIS: 
INVESTIGATIONS: 
1) Blood Glucose (Fasting) :              mg/dl 
2) Blood Urea                      :              mg/dl 
3) Serum Creatinine            :              mg/dl 
4) Creatinine Clearance      :              ml/min.   
5) Serum Fetuin-A              :              g/L  
6) Serum hsCRP                 :              mg/L 
7) Serum Calcium               :              mg/dl 
8) Serum Phosphorus          :              mg/dl   
9) Ca X P                             :   mg2/dl2 
10) Serum Albumin               :              g/dl 
11) Serum Lipid Profile: 
         Total Cholesterol    :   mg/dl 
         Triglycerides          :  mg/dl 
         HDL-C                   :  mg/dl 
         LDL-C                    :  mg/dl 
         VLDL-C                 :  mg/dl 
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
                         Dr.P.Deepa, postgraduate student in the department of 
Biochemistry, Thanjavur Medical College, Thanjavur is doing a study on 
serum Fetuin-A level in patients with chronic kidney disease. The procedures 
have been explained to me clearly. I understand that there are no risks involved 
in the above procedures. I hereby give my consent to participate in the study. 
The data obtained here may be used for research and publication. 
 
Signature: 
 
Name: 
 
Place:  
